<SEC-DOCUMENT>0001213900-25-106723.txt : 20251105
<SEC-HEADER>0001213900-25-106723.hdr.sgml : 20251105
<ACCEPTANCE-DATETIME>20251105172612
ACCESSION NUMBER:		0001213900-25-106723
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20251105
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251105
DATE AS OF CHANGE:		20251105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MoonLake Immunotherapeutics
		CENTRAL INDEX KEY:			0001821586
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39630
		FILM NUMBER:		251455241

	BUSINESS ADDRESS:	
		STREET 1:		DORFSTRASSE 29
		CITY:			ZUG
		STATE:			V8
		ZIP:			6300
		BUSINESS PHONE:		41 41 510 8022

	MAIL ADDRESS:	
		STREET 1:		DORFSTRASSE 29
		CITY:			ZUG
		STATE:			V8
		ZIP:			6300

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Helix Acquisition Corp
		DATE OF NAME CHANGE:	20200818
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0264149-8k_moonlake.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:MLTX="http://moonlaketx.com/20251105">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_MLTX_moonlaketx.com_20251105 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20251105_20251105 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001821586 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-11-05" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-11-05" id="Fact000004" name="dei:EntityCentralIndexKey">0001821586</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="mltx-20251105.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-11-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-05</xbrli:startDate>
        <xbrli:endDate>2025-11-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b></b></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 50%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <span id="xdx_909_edei--DocumentType_c20251105__20251105_znECWTCzsiGd"><ix:nonNumeric contextRef="AsOf2025-11-05" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span>&#160;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>PURSUANT TO SECTION 13 or 15(d) of the</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Date of Report (Date of earliest event reported):
<span id="xdx_908_edei--DocumentPeriodEndDate_c20251105__20251105_z0wPOmk49tig"><ix:nonNumeric contextRef="AsOf2025-11-05" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">November 5, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_90D_edei--EntityRegistrantName_c20251105__20251105_zClAMsdZOuNh"><ix:nonNumeric contextRef="AsOf2025-11-05" id="Fact000011" name="dei:EntityRegistrantName">MOONLAKE IMMUNOTHERAPEUTICS</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 32%"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20251105__20251105_zBxTJ19GiBe"><ix:nonNumeric contextRef="AsOf2025-11-05" format="ixt-sec:edgarprovcountryen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Cayman Islands</ix:nonNumeric></span></b></span></td>
    <td style="padding: 0pt 0pt 1.5pt; vertical-align: bottom; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 32%"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--EntityFileNumber_c20251105__20251105_zG5semXccLqa"><ix:nonNumeric contextRef="AsOf2025-11-05" id="Fact000013" name="dei:EntityFileNumber">001-39630</ix:nonNumeric></span></b></span></td>
    <td style="padding: 0pt 0pt 1.5pt; vertical-align: bottom; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 32%"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20251105__20251105_zKTw4euD2iKl"><ix:nonNumeric contextRef="AsOf2025-11-05" id="Fact000014" name="dei:EntityTaxIdentificationNumber">98-1711963</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(State or Other Jurisdiction <br/>
of Incorporation)</span></td>
    <td style="padding: 0pt; vertical-align: top; text-align: center">&#160;</td>
    <td style="padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Commission File Number)</span></td>
    <td style="padding: 0pt; vertical-align: top; text-align: center">&#160;</td>
    <td style="padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(IRS Employer<br/>
 Identification No.)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityAddressAddressLine1_c20251105__20251105_zezC5TqXeEVh"><ix:nonNumeric contextRef="AsOf2025-11-05" id="Fact000015" name="dei:EntityAddressAddressLine1">Dorfstrasse 29</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityAddressPostalZipCode_c20251105__20251105_zfHWLNSZ2fJd"><ix:nonNumeric contextRef="AsOf2025-11-05" id="Fact000016" name="dei:EntityAddressPostalZipCode">6300</ix:nonNumeric></span> <span id="xdx_90A_edei--EntityAddressCityOrTown_c20251105__20251105_zwgM8FZMn8q9"><ix:nonNumeric contextRef="AsOf2025-11-05" id="Fact000017" name="dei:EntityAddressCityOrTown">Zug</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityAddressCountry_c20251105__20251105_zJAnoW7K2pe"><ix:nonNumeric contextRef="AsOf2025-11-05" format="ixt-sec:countrynameen" id="Fact000018" name="dei:EntityAddressCountry">Switzerland</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices and Zip
Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90E_edei--CityAreaCode_c20251105__20251105_z0Qvlw2PD9W8"><ix:nonNumeric contextRef="AsOf2025-11-05" id="Fact000019" name="dei:CityAreaCode">41</ix:nonNumeric></span> <span id="xdx_907_edei--LocalPhoneNumber_c20251105__20251105_z4pbGebRJBIk"><ix:nonNumeric contextRef="AsOf2025-11-05" id="Fact000020" name="dei:LocalPhoneNumber">415108022</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s Telephone Number, Including
Area Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="background-color: white"><b>N/A</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="background-color: white">(Former Name
or Former Address, if Changed Since Last Report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_edei--WrittenCommunications_c20251105__20251105_zVl7523U3He9"><ix:nonNumeric contextRef="AsOf2025-11-05" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_edei--SolicitingMaterial_c20251105__20251105_zr0RLdghqXI4"><ix:nonNumeric contextRef="AsOf2025-11-05" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_edei--PreCommencementTenderOffer_c20251105__20251105_zZx53G1Dq50k"><ix:nonNumeric contextRef="AsOf2025-11-05" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20251105__20251105_zyngUhm3kLSd"><ix:nonNumeric contextRef="AsOf2025-11-05" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 32%"><span style="font-family: Times New Roman, Times, Serif"><b>Title of each class</b></span></td>
    <td style="padding: 0pt 0pt 1.5pt; vertical-align: bottom; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 32%"><span style="font-family: Times New Roman, Times, Serif"><b>Trading Symbol(s)</b></span></td>
    <td style="padding: 0pt 0pt 1.5pt; vertical-align: bottom; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 32%"><span style="font-family: Times New Roman, Times, Serif"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--Security12bTitle_c20251105__20251105_zYo7WTYjQCs6"><ix:nonNumeric contextRef="AsOf2025-11-05" id="Fact000025" name="dei:Security12bTitle">Class A ordinary share, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="padding: 0pt; vertical-align: top; text-align: center">&#160;</td>
    <td style="padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_edei--TradingSymbol_c20251105__20251105_z2PPkHgiuJv7"><ix:nonNumeric contextRef="AsOf2025-11-05" id="Fact000026" name="dei:TradingSymbol">MLTX</ix:nonNumeric></span></span></td>
    <td style="padding: 0pt; vertical-align: top; text-align: center">&#160;</td>
    <td style="padding: 0pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The <span id="xdx_900_edei--SecurityExchangeName_c20251105__20251105_zUqJRcHPIQWi"><ix:nonNumeric contextRef="AsOf2025-11-05" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_edei--EntityEmergingGrowthCompany_c20251105__20251105_z3pTyt2crSSc"><ix:nonNumeric contextRef="AsOf2025-11-05" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01. Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">On November 5, 2025,
MoonLake Immunotherapeutics (the &#8220;Company&#8221;) entered into an underwriting agreement (&#8220;Underwriting
Agreement&#8221;) with Leerink Partners LLC as the underwriter named therein (the &#8220;Underwriter&#8221;), to issue and sell
7,142,857 Class A ordinary shares, par value $0.0001 per share (the &#8220;Shares&#8221;), at an offering price of $10.50 per share
(the &#8220;Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">The gross proceeds from the Offering are expected
to be $75 million before deducting underwriting discounts and offering expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">The Shares described
above were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-274286), which became effective on September
11, 2023. A prospectus supplement dated November 5, 2025 relating to and describing the terms of the Offering was filed with the
U.S. Securities and Exchange Commission on November 5, 2025. The Offering is expected to close on November 6, 2025, subject to the
satisfaction of customary closing conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">In the Underwriting Agreement, the Company agreed
to indemnify the Underwriter against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribute
payments that the Underwriter may be required to make because of such liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">A copy of the Underwriting Agreement is filed
as Exhibit 1.1 and is incorporated herein by reference. The foregoing description of the Underwriting Agreement does not purport to be
complete and is qualified in its entirety by reference to such exhibit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">Walkers (Cayman) LLP,
Cayman counsel to the Company, has issued an opinion to the Company, dated November 5, 2025, regarding the validity of the issuance
and sale of the Shares in the Offering. A copy of the opinion is filed herewith as Exhibit 5.1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt; width: 9%"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration: none">Exhibit No.</span></b></span></td>
    <td style="padding: 0pt 0pt 1.5pt; text-indent: 0pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt; width: 90%"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration: none">Description</span></b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">1.1</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><a href="ea026414901ex1-1_moonlake.htm"><span style="font-family: Times New Roman, Times, Serif">Underwriting
Agreement, dated November 5, 2025, by and between MoonLake Immunotherapeutics and Leerink Partners LLC</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">5.1</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><a href="ea026414901ex5-1_moonlake.htm"><span style="font-family: Times New Roman, Times, Serif">Opinion of Walkers (Cayman) LLP</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">23.1</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><a href="ea026414901ex5-1_moonlake.htm"><span style="font-family: Times New Roman, Times, Serif">Consent of Walkers (Cayman) LLP (contained in Exhibit 5.1)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">104</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="2" style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>MOONLAKE IMMUNOTHERAPEUTICS</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt; width: 60%">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt; width: 5%">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt; width: 35%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Date: November 5, 2025</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration: none">/s/ Matthias Bodenstedt</span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Name:</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Matthias Bodenstedt</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Title:</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Chief Financial Officer</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwkAMhU/QO4RZS51W6qI7LSpiFSlF3A42ymA7KZnxp0fylk5bxBAIyXvfixATsaG1rpHhvCxyKLFpa+UQCrwio7mgd2TbXQp+FnjT1rEyblh/YEaeQc/Mw5ny98H51BarFKJoKpNpnIBMUhnBYi+CXs/IXHWFxmlVgzIVHJla1ugUd2NCqd5kqOmGTydkq8n4uFCO8gdiGcVwoKd6Ed8t5HkmgslQgdgwPVrvWr0dmp6EVY2Nf2dH+t/BF79YSkc= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ea026414901ex1-1_moonlake.htm
<DESCRIPTION>UNDERWRITING AGREEMENT, DATED NOVEMBER 5, 2025, BY AND BETWEEN MOONLAKE IMMUNOTHERAPEUTICS AND LEERINK PARTNERS LLC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>Execution Version</I></B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MOONLAKE IMMUNOTHERAPEUTICS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(a Cayman Islands exempted company)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">7,142,857 Ordinary Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNDERWRITING AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">November 5, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leerink Partners LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">as Representative of the several Underwriters </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o Leerink Partners LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">53 State Street, 40th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boston, MA 02109</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MoonLake Immunotherapeutics,
a Cayman Islands exempted company (the &ldquo;<U>Company</U>&rdquo;), confirms its agreement with Leerink Partners LLC (&ldquo;<U>Leerink
Partners</U>&rdquo;) and each of the other Underwriters named in <U>Schedule&nbsp;A</U> hereto (collectively, the &ldquo;<U>Underwriters</U>,&rdquo;
which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for which Leerink Partners is
acting as representative (in such capacity, the &ldquo;<U>Representative</U>&rdquo;), with respect to the sale by the Company and the
purchase by the Underwriters, acting severally and not jointly, of the respective numbers of Class A ordinary shares, par value $0.0001
per share, of the Company (&ldquo;<U>Ordinary Shares</U>&rdquo;) set forth in <U>Schedule&nbsp;A</U> hereto (the &ldquo;<U>Securities</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company understands that
the Underwriters propose to make a public offering of the Securities as soon as the Representative deems advisable after this Underwriting
Agreement (this &ldquo;<U>Agreement</U>&rdquo;) has been executed and delivered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has filed with
the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) a shelf registration statement on Form&nbsp;S-3 (No. 333-274286),
covering the public offering and sale of certain securities, including the Securities, under the Securities Act of 1933, as amended (the
&ldquo;<U>1933 Act</U>&rdquo;) and the rules and regulations of the Commission promulgated thereunder (the &ldquo;<U>1933 Act Regulations</U>&rdquo;),
which shelf registration statement was declared effective on September 11, 2023 under the 1933 Act. Such registration statement, as of
any time, means such registration statement as amended by any post-effective amendments thereto at such time, including the exhibits and
any schedules thereto at such time, the documents incorporated or deemed to be incorporated by reference therein at such time pursuant
to Item 12 of Form S-3 under the 1933 Act and the documents otherwise deemed to be a part thereof as of such time pursuant to Rule 430B
under the 1933 Act Regulations (&ldquo;<U>Rule 430B</U>&rdquo;), and is referred to herein as the &ldquo;Registration Statement;&rdquo;
provided, however, that the &ldquo;Registration Statement&rdquo; without reference to a time means such registration statement as amended
by any post-effective amendments thereto as of the time of the first contract of sale for the Securities, which time shall be considered
the &ldquo;new effective date&rdquo; of such registration statement with respect to the Securities within the meaning of paragraph (f)(2)
of Rule 430B, including the exhibits and schedules thereto as of such time, the documents incorporated or deemed incorporated by reference
therein at such time pursuant to Item 12 of Form S-3 under the 1933 Act and the documents otherwise deemed to be a part thereof as of
such time pursuant to the Rule 430B. Any registration statement filed pursuant to Rule 462(b) of the 1933 Act Regulations is herein called
the &ldquo;<U>Rule 462(b) Registration Statement</U>&rdquo; and, after such filing, the term &ldquo;Registration Statement&rdquo; shall
include the Rule 462(b) Registration Statement. The base prospectus filed as part of the Registration Statement in the form in which has
most recently been filed with the Commission on or prior to the date of this Agreement, together with any documents incorporated by reference
therein, is herein called the &ldquo;Base Prospectus.&rdquo; Each preliminary prospectus used in connection with the offering of the Securities,
if any, including the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of Form S-3 under the
1933 Act, are collectively referred to herein as a &ldquo;preliminary prospectus.&rdquo; Promptly after execution and delivery of this
Agreement, the Company will prepare and file a final prospectus relating to the Securities in accordance with the provisions of Rule 424(b)
under the 1933 Act Regulations (&ldquo;Rule 424(b)&rdquo;). The final prospectus, in the form first furnished or made available to the
Underwriters for use in connection with the offering of the Securities, including the documents incorporated or deemed to be incorporated
by reference therein pursuant to Item 12 of Form S-3 under the 1933 Act, are collectively referred to herein as the &ldquo;Prospectus.&rdquo;
For purposes of this Agreement, all references to the Registration Statement, Base Prospectus, any preliminary prospectus, the Prospectus
or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic
Data Gathering, Analysis and Retrieval system (or any successor system) (&ldquo;<U>EDGAR</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;Applicable
Time&rdquo; means 7:05 A.M., New York City time, on November 5, 2025 or such other time as agreed by the Company and the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;General Disclosure
Package&rdquo; means the Base Prospectus, as most recently amended or supplemented prior to the Applicable Time (including any documents
incorporated by reference therein), together with any Issuer Free Writing Prospectuses issued at or prior to the Applicable Time, if permitted,
and the information included on <U>Schedule&nbsp;B-1</U> hereto, all considered together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;Issuer Free
Writing Prospectus&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433 of the 1933 Act Regulations (&ldquo;<U>Rule
433</U>&rdquo;), including without limitation any &ldquo;free writing prospectus&rdquo; (as defined in Rule 405 of the 1933 Act Regulations
(&ldquo;<U>Rule 405</U>&rdquo;)) relating to the Securities that is (i) required to be filed with the Commission by the Company, (ii)
a &ldquo;road show for an offering that is a written communication&rdquo; within the meaning of Rule 433(d)(8)(i), whether or not required
to be filed with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description
of the Securities or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with
the Commission or, if not required to be filed, in the form retained in the Company&rsquo;s records pursuant to Rule 433(g).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;Testing-the-Waters
Communication&rdquo; means any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the 1933
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;Written Testing-the-Waters
Communication&rdquo; means any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the
1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All references in this Agreement
to financial statements and schedules and other information which is &ldquo;contained,&rdquo; &ldquo;included&rdquo; or &ldquo;stated&rdquo;
(or other references of like import) in the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include
all such financial statements and schedules and other information incorporated or deemed incorporated by reference in the Registration
Statement, any preliminary prospectus or the Prospectus, as the case may be, prior to the execution and delivery of this Agreement; and
all references in this Agreement to amendments or supplements to the Registration Statement, any preliminary prospectus or the Prospectus
shall be deemed to include the filing of any document under the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder (collectively, the &ldquo;<U>1934 Act</U>&rdquo;), incorporated or deemed to be incorporated by reference in the
Registration Statement, such preliminary prospectus or the Prospectus, as the case may be, at or after the execution and delivery of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 1. <U>Representations
and Warranties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)   <I>Representations
and Warranties by the Company</I>. The Company represents and warrants to each Underwriter as of the date hereof, the Applicable Time
and the Closing Time (as defined below), and agrees with each Underwriter, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)   <U>Registration
Statement and Prospectuses</U>. The Company meets the requirements for use of Form S-3 under the 1933 Act. Each of the Registration Statement
and any post-effective amendment thereto has become effective under the 1933 Act. No stop order suspending the effectiveness of the Registration
Statement or any post-effective amendment thereto has been issued by the Commission under the 1933 Act, no order preventing or suspending
the use of any preliminary prospectus or the Prospectus has been issued by the Commission and no proceedings for any of those purposes
have been instituted by the Commission or are pending or, to the Company&rsquo;s knowledge, contemplated by the Commission. The Company
has complied with each request (if any) from the Commission for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Each of the Registration
Statement and any post-effective amendment thereto, at the time of its effectiveness and at each deemed effective date with respect to
the Underwriters pursuant to Rule 430B(f)(2) under the 1933 Act Regulations, complied in all material respects with the requirements of
the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus, if any, the Prospectus and any amendment or supplement thereto,
at the time each was filed with the Commission, complied in all material respects with the requirements of the 1933 Act and the 1933 Act
Regulations. Each preliminary prospectus, if any, delivered to the Underwriters for use in connection with this offering and the Prospectus
was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent
permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">The documents incorporated
or deemed to be incorporated by reference in the Registration Statement and the Prospectus, when they became effective or at the time
they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the 1934
Act and the rules and regulations of the Commission under the 1934 Act (the &ldquo;<U>1934 Act Regulations</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">The Registration
Statement, any preliminary prospectus and the Prospectus, and the filing of the Registration Statement, any preliminary prospectus and
the Prospectus with the Commission have been duly authorized by and on behalf of the Company, and the Registration Statement has been
duly executed pursuant to such authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)   <U>Accurate
Disclosure</U>. Neither the Registration Statement nor any amendment thereto, at its effective time, at the Closing Time, contained, contains
or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading. As of the Applicable Time, neither of (A) the General Disclosure Package,
nor (B) any individual Written Testing-the-Waters Communication, when considered together with the General Disclosure Package, included,
includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading. Neither the Prospectus nor
any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of any filing with the Commission
pursuant to Rule 424(b), or at the Closing Time, included, includes or will include an untrue statement of a material fact or omitted,
omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading. The documents incorporated or deemed to be incorporated by reference in the Registration Statement,
the General Disclosure Package and the Prospectus, at the time the Registration Statement became effective or when such documents incorporated
by reference were filed with the Commission, as the case may be, when read together with the other information in the Registration Statement,
the General Disclosure Package or the Prospectus, as the case may be, did not and will not include an untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">The representations
and warranties in this subsection shall not apply to statements in or omissions from the Registration Statement (or any amendment thereto),
the General Disclosure Package or the Prospectus (or any amendment or supplement thereto, including any prospectus wrapper) made in reliance
upon and in conformity with written information furnished to the Company by any Underwriter through the Representative expressly for use
therein. For purposes of this Agreement, the only information so furnished shall be the information in the first sentence of the first
paragraph under the caption &ldquo;Underwriting&mdash;Discounts and Commissions,&rdquo; the second sentence of the first paragraph under
the caption &ldquo;Underwriting&mdash;Price Stabilization, Short Positions and Penalty Bids&rdquo; in each case contained in the Prospectus
(collectively, the &ldquo;<U>Underwriter Information</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)   <U>[Reserved]</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv)   <U>Testing-the-Waters
Materials</U>. The Company (A) has not engaged in any Testing-the-Waters Communication other than Testing-the-Waters Communications with
the consent of the Representative with entities that are qualified institutional buyers within the meaning of Rule 144A under the 1933
Act or institutions that are accredited investors within the meaning of Rule 501 under the 1933 Act and (B) has not authorized anyone
other than the Representative to engage in Testing-the-Waters Communications. The Company reconfirms that the Representative has been
authorized to act on its behalf in undertaking Testing-the-Waters Communications specifically authorized by the Company. The Company has
not distributed any Written Testing-the-Waters Communications other than those listed on <U>Schedule B-2</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)   <U>Company
Not Ineligible Issuer</U>. At the time the Company or another offering participant made a <I>bona fide</I> offer (within the meaning of
Rule 164(h)(2) of the 1933 Act Regulations) of the Securities and at the date hereof, the Company was not and is not an &ldquo;ineligible
issuer,&rdquo; as defined in Rule 405, without taking account of any determination by the Commission pursuant to Rule 405 that it is not
necessary that the Company be considered an ineligible issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vi)   <U>[Reserved]</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vii)   <U>Independent
Accountants</U>. Baker Tilly US, LLP, whose report on the consolidated financial statements of the Company is filed with the Commission
as part of the Company&rsquo;s most recent annual report on Form 10-K filed with the Commission and incorporated by reference in the Registration
Statement, the General Disclosure Package and the Prospectus, is (i) an independent registered public accounting firm as required by the
1933 Act, the 1934 Act and the rules of the Public Company Accounting Oversight Board (&ldquo;<U>PCAOB</U>&rdquo;), (ii) in compliance
with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X under the 1933 Act and
(iii) a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not
requested such registration to be withdrawn. Baker Tilly US, LLP has not been engaged by the Company to perform any &ldquo;prohibited
activities&rdquo; or provided to the Company any &ldquo;non-audit services&rdquo; (as defined in Section 10A of the 1934 Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(viii)   <U>Financial
Statements; Non-GAAP Financial Measures</U>. The financial statements included or incorporated by reference in the Registration Statement,
the General Disclosure Package and the Prospectus, together with the related notes and schedules, present fairly in all material respects
the consolidated financial position of the Company and the Subsidiaries as of the dates indicated and the consolidated results of operations,
cash flows and changes in shareholders&rsquo; equity of the Company and the Subsidiaries for the periods specified and have been prepared
in compliance in all material respects with the requirements of the 1933 Act and 1934 Act and in conformity in all material respects with
United States generally accepted accounting principles (&ldquo;<U>GAAP</U>&rdquo;) applied on a consistent basis during the periods involved
(except as otherwise noted therein). To the extent applicable, any pro forma financial statements, information or data included or incorporated
by reference in the Registration Statement, the General Disclosure Package and the Prospectus comply in all material respects with the
requirements of Regulation S-X of the 1933 Act, including, without limitation, Article 11 thereof, fairly present, in all material respects,
the information set forth therein, and the assumptions used in the preparation of such pro forma financial statements and data are reasonable,
the pro forma adjustments used therein are appropriate to give effect to the circumstances referred to therein and the pro forma adjustments
have been properly applied to the historical amounts in the compilation of those statements and data. The other financial data set forth
or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus is accurately and fairly
presented and prepared, in all material respects, on a basis consistent with the financial statements and books and records of the Company.
There are no financial statements (historical or pro forma) that are required to be included or incorporated by reference in the Registration
Statement, the General Disclosure Package or the Prospectus that are not included or incorporated by reference therein as required. The
Company and the Subsidiaries do not have any material liabilities or obligations, direct or contingent (including any off-balance sheet
obligations), not disclosed in the Registration Statement, the General Disclosure Package and the Prospectus. All disclosures contained
in the Registration Statement, the General Disclosure Package or the Prospectus that contain &ldquo;non-GAAP financial measures&rdquo;
(as such term is defined by the rules and regulations of the Commission) comply, in all material respects, with Regulation G under the
1934 Act and Item 10 of Regulation S-K under the 1933 Act, to the extent applicable. The statistical, industry-related and market-related
data included or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus were obtained
or derived from sources which the Company reasonably and in good faith believes are reliable and accurate, in all material respects, such
data agree with the sources from which they are derived, and the Company has obtained the written consent to the use of such data from
such sources to the extent required. To the Company&rsquo;s knowledge, no person who has been suspended or barred from being associated
with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB,
has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial
data filed with the Commission as a part of the Registration Statement, the General Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ix)   <U>Compliance
with the Sarbanes-Oxley Act of 2002</U>. The Company is in compliance with, and there is and has been no failure on the part of the Company
and, to the Company&rsquo;s knowledge, any of the Company&rsquo;s directors or officers, in their capacities as such, to comply with,
any applicable provision of the Sarbanes-Oxley Act of 2002 and all rules and regulations promulgated thereunder or implementing the provisions
thereof (the &ldquo;<U>Sarbanes-Oxley Act</U>&rdquo;) and the rules and regulations promulgated in connection therewith, including Section
402 relating to loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x)   <U>No
Material Adverse Change in Business</U>. Subsequent to the respective dates as of which information is given in the Registration Statement
and the Prospectus and except as set forth in the Registration Statement, the General Disclosure Package or the Prospectus: (i) there
has been no material adverse change, or any development that could reasonably be expected to result in a material adverse change, in the
condition (financial or otherwise), earnings, results of operations, business, properties, operations, assets, liabilities or prospects
of the Company and its Subsidiaries, taken as a whole, whether or not arising from transactions in the ordinary course of business (a
&ldquo;<U>Material Adverse Effect</U>&rdquo;); (ii) neither the Company nor Company&rsquo;s &ldquo;subsidiaries&rdquo; (for purposes of
this Agreement, as defined in Rule 405 under the 1933 Act) (each, a &ldquo;<U>Subsidiary</U>&rdquo; and collectively, the &ldquo;<U>Subsidiaries</U>&rdquo;)
has (A) incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference
with its business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any
strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company
and its Subsidiaries, considered as one entity, (B) entered into any material transactions not in the ordinary course of business or (C)
issued or granted any shares of the Company or the Company&rsquo;s securities convertible into or exchangeable or exercisable for or that
represent the right to receive shares of the Company other than under the Share Plans; and (iii) there has not been any material decrease
in the share capital or any material increase in any short-term or long-term indebtedness of the Company or any of its Subsidiaries and
there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to the Company
or another Subsidiary, by any Subsidiary on any class of shares, or any repurchase or redemption by the Company or any of its Subsidiaries
of any class of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xi)   <U>Good
Standing of the Company</U>. The Company has been duly incorporated and is validly existing as an exempted company in good standing under
the laws of the Cayman Islands, with full corporate power and authority to acquire, own, lease and operate its properties, and to lease
the same to others, and to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus
and to enter into and perform its obligations under this Agreement. The Company is duly qualified to transact business and is in good
standing (where such concept exists) under the laws of each other jurisdiction that requires such qualification, whether by reason of
the ownership or leasing of property or the conduct of business, except to the extent that the failure to be so qualified or in good standing
outside of the Cayman Islands could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xii)   <U>Good
Standing of the Company&rsquo;s Subsidiaries</U>. Each of the Subsidiaries has been duly organized and is validly existing in good standing
(where such concept exists) under the laws of the jurisdiction of its organization and has full power and authority to acquire, own, lease
and operate its properties, and to conduct its business as described in the Registration Statement, the General Disclosure Package and
the Prospectus. Each Subsidiary is duly qualified to transact business and is in good standing (where such concept exists) under the laws
of each jurisdiction that requires such qualification, whether by reason of the ownership or leasing of property or the conduct of business,
except to the extent that the failure to be so qualified or in good standing could not reasonably be expected, individually or in the
aggregate, to have a Material Adverse Effect. All of the issued and outstanding share capital or other equity or ownership interests of
each Subsidiary has been duly authorized and validly issued, is fully paid and nonassessable, has been issued in compliance with federal,
state and local securities laws and, except as described in the Registration Statement, the General Disclosure Package and the Prospectus,
is owned by the Company, directly or through other wholly-owned Subsidiaries, free and clear of any security interest, mortgage, pledge,
lien, encumbrance or adverse claim. The Company does not own or control, directly or indirectly, any corporation, association or other
entity, other than the Subsidiaries listed on Exhibit 21.1 to the Company&rsquo;s most recent Annual Report on Form 10-K filed with the
Commission. No Subsidiary is prohibited or restricted, directly or indirectly, from paying dividends to the Company, from making any other
distribution with respect to such Subsidiary&rsquo;s equity securities, from repaying to the Company or any other Subsidiary any amounts
that may from time to time become due under any loans or advances to such Subsidiary from the Company or from transferring any property
or assets to the Company or to any other Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xiii)   <U>Capitalization</U>.
The Company has the authorized and outstanding capitalization as set forth in the Company&rsquo;s most recent periodic report on Form
10-K or Form 10-Q, as the case may be, as of the dates referred to therein (subject, in each case, to the issuance of Securities under
this Agreement, the issuance of Ordinary Shares upon exercise of share options and warrants disclosed as outstanding as of the date hereof
in the Registration Statement, the General Disclosure Package and the Prospectus and the grant of options under existing share option
plans described in the Registration Statement, the General Disclosure Package and the Prospectus). The Ordinary Shares conform in all
material respects to the description thereof contained in the Registration Statement, the General Disclosure Package and the Prospectus,
including under the heading &ldquo;Description of Shares.&rdquo; All of the issued and outstanding share capital or other equity or ownership
interest of the Company (including the Ordinary Shares) has been duly authorized and validly issued and is fully paid and nonassessable,
has been issued in compliance with all federal, state and local securities laws and is free and clear of any security interest, mortgage,
pledge, lien, encumbrance or adverse claim. None of the outstanding capital shares of the Company were issued in violation of any preemptive
rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. Except as summarized in
the Registration Statement, the General Disclosure Package and the Prospectus, there are no authorized or outstanding options, warrants,
preemptive rights, rights of first refusal or other rights to purchase or subscribe for, or equity or debt securities convertible into
or exchangeable or exercisable for, any share capital of the Company or any of its Subsidiaries or to which the Company or any of its
Subsidiaries is a party or by which any of them may be bound. The descriptions of the Company&rsquo;s equity incentive plan, share option
plans and other share plans or arrangements described in the Prospectus and in effect as of the date hereof (collectively, the &ldquo;<U>Share
Plans</U>&rdquo;) and the options or other rights granted thereunder, set forth in the Prospectus accurately and fairly present the information
required to be shown with respect to such Share Plans and the options or other rights granted thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xiv)   <U>Authorization
of Agreement</U>. This Agreement has been duly authorized, executed and delivered by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xv)   <U>Authorization
and Description of Securities</U>. The Securities to be purchased by the Underwriters from the Company have been duly authorized for issuance
and sale to the Underwriters pursuant to this Agreement and, when issued and delivered by the Company pursuant to this Agreement against
payment of the consideration set forth herein, will be validly issued and fully paid and non-assessable; and the issuance of the Securities
is not subject to the preemptive or other similar rights of any securityholder of the Company. The Ordinary Shares conform to all statements
relating thereto contained in the Registration Statement, the General Disclosure Package and the Prospectus and such description conforms
to the rights set forth in the instruments defining the same. No holder of Securities will be subject to personal liability by reason
of being such a holder. The issuance and sale of the Securities as contemplated hereby shall not be subject to any preemptive rights,
rights of first refusal or other similar rights to subscribe for or purchase the Securities. When issued and delivered by the Company
against payment therefor pursuant to this Agreement, and, following the transfer agent of the Company updating the register of members
of the Company to reflect the issuance of any such Securities, the purchasers of the Securities issued and sold hereunder will acquire
good, marketable and valid title to such Securities, free and clear of all pledges, liens, security interests, charges, claims or encumbrances.
The issuance and sale of the Securities as contemplated hereby will not cause any holder of any share capital, securities convertible
into or exchangeable or exercisable for share capital or options, warrants or other rights to purchase share capital or any other securities
of the Company to have any right to acquire any preference shares of the Company. There are no restrictions upon the voting or transfer
of the Ordinary Shares under the Company&rsquo;s Memorandum and Articles of Association, as amended (the &ldquo;<U>Memorandum and Articles
of Association</U>&rdquo;), other similar organizational document or any agreement or other instrument to which the Company is a party
or otherwise filed as an exhibit to the Company&rsquo;s most recent annual report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xvi)   <U>Registration
Rights</U>. There are no persons (as such term is defined in Rule 1-02 of Regulation S-X promulgated under the 1933 Act) with registration
or other similar rights to have any equity or debt securities of the Company registered for sale under the Registration Statement or included
in the offering contemplated by this Agreement, except for such rights as have been duly waived in a writing previously furnished to the
Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xvii)   <U>Absence
of Violations, Defaults and Conflicts</U>. Neither the Company nor any Subsidiary is in violation or default of (i) any provision of its
Memorandum and Articles of Association, bylaws, limited liability company agreement, certificate or agreement of limited or general partnership,
or other similar organizational documents, as the case may be, of such entity, (ii) the terms of any indenture, contract, lease, mortgage,
deed of trust, note agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which it is a party
or bound or to which its property or assets is subject (collectively, &ldquo;<U>Agreements and Instruments</U>&rdquo;), or (iii) any statute,
law, rule, regulation, judgment, order or decree of any court, regulatory body, administrative agency, governmental body, arbitrator or
other authority having jurisdiction over the Company, any of its Subsidiaries or any of their respective properties or assets (each, a
&ldquo;<U>Governmental Entity</U>&rdquo;), as applicable, except, in the case of clauses (ii) and (iii) above, for any such default or
violation that would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. The execution,
delivery and performance of this Agreement and the consummation of the transactions contemplated herein and in the Registration Statement,
the General Disclosure Package and the Prospectus (including the issuance and sale of the Securities and the use of the proceeds from
the sale of the Securities as described therein under the caption &ldquo;<U>Use of Proceeds</U>&rdquo;) and compliance by the Company
with its obligations hereunder have been duly authorized by all necessary corporate action and do not and will not, whether with or without
the giving of notice or passage of time or both, conflict with or constitute a breach of, or default or Repayment Event (as defined below)
under, or result in the creation or imposition of any lien, charge or encumbrance upon any properties or assets of the Company or its
Subsidiaries pursuant to, the Agreements and Instruments (except for such conflicts, breaches, defaults or Repayment Events or liens,
charges or encumbrances that would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect), nor
will such action result in any violation of the provisions of the charter, by-laws or similar organizational document of the Company or
its Subsidiaries or any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Entity. As used herein, a
&ldquo;<U>Repayment Event</U>&rdquo; means any event or condition which gives the holder of any note, debenture or other evidence of indebtedness
(or any person acting on such holder&rsquo;s behalf) the right to require the repurchase, redemption or repayment of all or a portion
of such indebtedness by the Company or its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xviii)   <U>1934
Act Registration and Nasdaq Listing</U>. The Company is subject to and in compliance in all material respects with the reporting requirements
of Section 13 or Section 15(d) of the 1934 Act. The Ordinary Shares are registered pursuant to Section 12(b) of the 1934 Act and are listed
on the Nasdaq Capital Market (&ldquo;<U>Nasdaq</U>&rdquo;), and the Company has taken no action designed to, or reasonably likely to have
the effect of, terminating the registration of the Ordinary Shares under the 1934 Act or delisting the Ordinary Shares from Nasdaq, nor
has the Company received any notification that the Commission or Nasdaq is contemplating terminating such registration or listing. The
Company is in compliance with the current listing standards of Nasdaq. The Company has filed a Notification of Listing of Additional Shares
with Nasdaq with respect to the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xix)   <U>Absence
of Labor Dispute</U>. No labor dispute with the employees of the Company or any of its Subsidiaries exists or, to the Company&rsquo;s
knowledge, is threatened or imminent, and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees
of any of its or any of its Subsidiaries&rsquo; principal suppliers, manufacturers, contractors or customers, in each case that would
reasonably be expected to result in a Material Adverse Effect. None of the employees of the Company or any of its Subsidiaries is represented
by a union and, to the knowledge of the Company, no union organizing activities are taking place. Neither the Company nor any of its Subsidiaries
has violated (or received notice of any violation of) any federal, state or local law or foreign law relating to the discrimination in
hiring, promotion or pay of employees, nor any applicable wage or hour laws, or the rules and regulations thereunder, or analogous foreign
laws and regulations, which would, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xx)   <U>Absence
of Proceedings</U>. There is no legal or governmental proceeding to which the Company or any of its Subsidiaries is a party or of which
any property or assets of the Company or any of its Subsidiaries is the subject, including any proceeding before the U.S. Food and Drug
Administration (&ldquo;<U>FDA</U>&rdquo;), the European Medicines Agency (&ldquo;<U>EMA</U>&rdquo;) or any foreign, local, national or
other governmental agency with jurisdiction over the types of products being developed by the Company that is required to be described
in the Registration Statement, the General Disclosure Package or the Prospectus and is not described therein, or which, individually or
in the aggregate, if determined adversely to the Company or any of its Subsidiaries, could reasonably be expected to have a Material Adverse
Effect; and, to the knowledge of the Company, no such proceedings are threatened or contemplated by governmental or regulatory authorities
or threatened by others. The Company and its Subsidiaries (i) have not received notice of any claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action from any governmental authority or third party alleging that any product operation
or activity is in violation of any Applicable Laws or Governmental Permits and have no knowledge that any such governmental authority
or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding and (ii) have not received
notice that any governmental authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any Governmental
Permits and the Company has no knowledge that any such governmental authority is considering such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxi)   <U>Accuracy
of Exhibits</U>. There is no statute, regulation, contract, agreement or other document required to be described in the Registration Statement,
the General Disclosure Package or the Prospectus, or to be filed as an exhibit to the Registration Statement which is not described or
filed as required. The statements set forth or incorporated by reference in the Prospectus, insofar as they purport to constitute summaries
of the terms of the statutes, regulations, contracts, agreements or other documents described and filed, constitute accurate summaries
of the terms thereof in all material respects. The statements set forth or incorporated by reference in the Prospectus under the headings
&ldquo;Material U.S. Federal Income Tax Consequences to Non-U.S. Holders,&rdquo; &ldquo;Risk Factors,&rdquo; &ldquo;Business&mdash;Intellectual
Property,&rdquo; &ldquo;Business&mdash;The Merck Healthcare KGaA (Darmstadt, Germany) License Agreement,&rdquo; &ldquo;Business&mdash;Government
Regulation,&rdquo; &ldquo;Legal Proceedings,&rdquo; and &ldquo;Description of Shares,&rdquo; insofar as such statements summarize legal
matters, agreements, documents or proceedings discussed therein, are accurate and fair summaries, in all material respects, of such legal
matters, agreements, documents or proceedings. Neither the Company nor any of its Subsidiaries has sent or received any communication
regarding termination of, or intent not to renew or render performance under, any of the contracts or agreements referred to or described
in the Prospectus or any free writing prospectus, or referred to or described in, or filed as an exhibit to, the Registration Statement,
and no such termination or non-renewal has been threatened by the Company or any of its Subsidiaries or, to the Company&rsquo;s knowledge,
any other party to any such contract or agreement, which threat of termination or non-renewal has not been rescinded as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxii)   <U>Absence
of Further Requirements</U>. No consent, approval, license, permit, qualification, authorization or other order or decree of, or registration
or filing with, any court or other governmental, taxing or regulatory authority or agency, is required for the Company&rsquo;s execution,
delivery and performance of this Agreement or consummation of the transactions contemplated hereby or by the Registration Statement, the
General Disclosure Package and the Prospectus (including the issuance and sale of the Securities hereunder), except such as have been
already obtained or made or as may be required under the 1933 Act, applicable state securities or Blue Sky laws, applicable rules of Nasdaq,
or Rule 5110 of the Financial Industry Regulatory Authority, Inc. (&ldquo;<U>FINRA</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxiii)   <U>Possession
of Licenses and Permits</U>. The Company and its Subsidiaries possess and are operating in compliance with such valid and current certificates,
authorizations or permits required by United States federal, state or foreign regulatory agencies or bodies to conduct their respective
businesses as currently conducted and as described in the Registration Statement, the General Disclosure Package and the Prospectus (collectively,
&ldquo;<U>Permits</U>&rdquo;), except for any such failure to possess or operate in compliance with as would not reasonably be expected
to have, individually or in the aggregate, a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is in violation
of, or in default under, any of the Permits or has received any written notice of proceedings relating to the revocation or modification
of, or non-compliance with, any such certificate, authorization or permit, which, individually or in the aggregate, if the subject of
an unfavorable decision, ruling or finding, could reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxiv)   The
Company and each of its Subsidiaries (i) are and have at all times been in full compliance with all laws, statutes, rules, regulations
or guidance applicable to the Company and its Subsidiaries and the ownership, testing, development, manufacture, packaging, processing,
use, distribution, marketing, advertising, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any pharmaceuticals
or biohazardous substances, materials or any other products developed, manufactured or distributed by the Company (including, without
limitation, from the FDA, EMA and any local or other governmental or regulatory authority performing functions similar to those performed
by the FDA or EMA) (collectively, &ldquo;<U>Applicable Laws</U>&rdquo;), except as could not, individually or in the aggregate, reasonably
be expected to result in a Material Adverse Effect, (ii) have not received any notice of adverse finding, warning letter, untitled letter
or other correspondence or notice from the FDA or any other federal, state or foreign governmental authority having authority over the
Company, any of its Subsidiaries or their activities alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates,
approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (collectively,
the &ldquo;<U>Governmental Permits</U>&rdquo;), (iii) have made all filings with, the appropriate local, or other governmental or regulatory
agencies or bodies that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses
as described in the Registration Statement, the General Disclosure Package and the Prospectus, except where any failures to possess or
make the same would not, singularly or in the aggregate, have a Material Adverse Effect, (iv)&nbsp;possess all material Governmental Permits
necessary to conduct their respective businesses as described in the Registration Statement, the General Disclosure Package and the Prospectus,
and such Governmental Permits are not in violation of any term of any such Governmental Permits, except where such violation could not,
individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, (v) have filed, obtained, maintained
or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments
as required by any Applicable Laws or Governmental Permits and that all such reports, documents, forms, notices, applications, records,
claims, submissions and supplements or amendments were complete and correct in all material respects on the date filed (or were corrected
or supplemented by a subsequent submission), and (vi) are not a party to any corporate integrity agreements, monitoring agreements, consent
decrees, settlement orders or similar agreements with or imposed by any governmental authority. All Governmental Permits are valid and
in full force and effect, except where the validity or failure to be in full force and effect would not, individually or in the aggregate,
have a Material Adverse Effect. Neither the Company nor any Subsidiary has received notification of any revocation, modification, suspension,
termination or invalidation (or proceedings related thereto) of any such Governmental Permit and the Company has no reason to believe
that any such Governmental Permit will not be renewed. Neither the Company, any of its Subsidiaries nor, to the Company&rsquo;s knowledge,
any of their respective directors, officers, employees or agents has been convicted of any crime under any Applicable Laws or has been
the subject of an FDA debarment proceeding. Neither the Company nor any of its Subsidiaries has been nor is now subject to the FDA&rsquo;s
Application Integrity Policy. To the Company&rsquo;s knowledge, neither the Company, any of its Subsidiaries nor any of its directors,
officers, employees or agents has made, or caused the making of, any false statements on, or material omissions from, any other records
or documentation prepared or maintained to comply with the requirements of the FDA or any other governmental authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxv)   <U>Title
to Property</U>. The Company and each of its Subsidiaries has good and marketable title in fee simple to all real property owned by them
and good and marketable title to all personal property owned by them that is material to their business (except with respect to intellectual
property, which is addressed exclusively in Section 1(xxvi) and Section 1(xxvii) below), in each case free and clear of all liens, encumbrances
and defects except such as do not materially affect the value of such property and do not interfere with the use made and proposed to
be made of such property by the Company or any Subsidiary; and any real property and buildings held under lease by the Company or any
of its Subsidiaries are held by them under valid, subsisting and enforceable leases (subject to the effects of (A) bankruptcy, insolvency,
fraudulent conveyance, fraudulent transfer, reorganization, moratorium or other similar laws relating to or affecting the rights or remedies
of creditors generally; (B) the application of general principles of equity (including, without limitation, concepts of materiality, reasonableness,
good faith and fair dealing, regardless of whether enforcement is considered in proceedings at law or in equity); and (C) applicable law
and public policy with respect to rights to indemnity and contribution) with such exceptions as are not material and do not interfere
with the use made and proposed to be made of such property and buildings by the Company or such Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxvi)   <U>Title
to Intellectual Property</U>. The Company and its Subsidiaries own or possess the right to use all inventions, patent applications, patents,
trademarks, trade names, service names, domain names, copyrights, trade secrets, know-how and other intellectual property (collectively,
&ldquo;<U>Intellectual Property</U>&rdquo;) as are (i) necessary or material for the conduct of their respective businesses as currently
conducted or as currently proposed to be conducted and as described in the Registration Statement, the General Disclosure Package and
the Prospectus and (ii) necessary or material for the commercialization of the products described in the Registration Statement, the General
Disclosure Package and the Prospectus as being under development. There is no pending or, to the Company&rsquo;s knowledge, threatened
(i) action, suit, proceeding, or claim by others challenging the rights of the Company or any of its Subsidiaries in or to any such Intellectual
Property that, if decided adversely to the Company or such Subsidiary would, individually or in the aggregate, have a Material Adverse
Effect, and the Company is unaware of any facts which would form a reasonable basis for any such claim; (ii) action, suit, proceeding,
or claim by others that the Company or any of its Subsidiaries infringes, misappropriates, or otherwise violates any Intellectual Property
of others that, if decided adversely to the Company or such Subsidiary would, individually or in the aggregate, have a Material Adverse
Effect, and the Company is unaware of any facts which would form a reasonable basis for any such claim; or (iii) action, suit, proceeding,
or claim by others challenging the validity, scope, or enforceability of any such Intellectual Property owned or licensed by the Company
or its Subsidiaries and the Company is unaware of any facts which would form a reasonable basis for any such claim. To the Company&rsquo;s
knowledge, the operation of the business of the Company and its Subsidiaries as now conducted, and as described in the Prospectus, and
in connection with the development and commercialization of the products described in the Prospectus does not infringe, misappropriate,
conflict with or otherwise violate any claim of any patent or published patent application of any other person or entity. There is no
prior art of which the Company or any of its Subsidiaries is aware that may render any patent owned or licensed by the Company or its
Subsidiaries invalid or any patent application owned or licensed by the Company or its Subsidiaries unpatentable which has not been disclosed
to the applicable government patent office. The Company&rsquo;s granted or issued patents, registered trademarks and registered copyrights
have been duly maintained and are in full force and effect, and none of the patents, trademarks and copyrights have been adjudged invalid
or unenforceable in whole or in part. The Company knows of no infringement, misappropriation or violation by others of any Intellectual
Property owned or licensed by the Company or its Subsidiaries which would reasonably be expected to have a Material Adverse Effect. Neither
the Company nor any of its Subsidiaries is a party to or bound by any options, licenses or agreements with respect to the Intellectual
Property of any other person or entity that are required to be set forth in the Prospectus and that are not described therein in all material
respects. The Company and its Subsidiaries have taken all reasonable steps necessary to secure their interests in the Intellectual Property
of the Company and its Subsidiaries from their employees and contractors and to protect the confidentiality of all of their confidential
information and trade secrets. None of the technology or intellectual property used by the Company and its Subsidiaries in its business
has been obtained or is being used by the Company or its Subsidiaries in violation of any contractual obligation binding on the Company
or its Subsidiaries, or, to the Company&rsquo;s knowledge, any of its officers, directors or employees or otherwise in violation of the
rights of any persons. No third party has been granted by the Company or its Subsidiaries rights to the Intellectual Property of the Company
or its Subsidiaries, including any rights that, if exercised, could enable such party to develop products competitive to those of the
Company as described in the Registration Statement, the General Disclosure Package and the Prospectus. All Intellectual Property owned
or exclusively licensed by the Company or its Subsidiaries are free and clear of all liens, encumbrances, defects or other restrictions
(other than non-exclusive licenses granted in the ordinary course of business), except those that could not reasonably be expected, individually
or in the aggregate, to have a Material Adverse Effect. The Company and its Subsidiaries are not subject to any judgment, order, writ,
injunction or decree of any court or any federal, state, local, foreign or other governmental department, commission, board, bureau, agency
or instrumentality, domestic or foreign, or any arbitrator, nor has it entered into or is it a party to any agreement made in settlement
of any pending or threatened litigation, which materially restricts or impairs their use of any Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxvii)   <U>Patents
and Patent Applications</U>. The Company has duly and properly filed or caused to be filed with the U.S. Patent and Trademark Office (the
&ldquo;<U>PTO</U>&rdquo;) and applicable foreign and international patent and trademark authorities all patents, trademarks, copyrights
and applications relating to the same owned by the Company and its Subsidiaries (the &ldquo;<U>Company Patent and Trademark Applications</U>&rdquo;).
To the knowledge of the Company, the Company has complied with the PTO&rsquo;s duty of candor and disclosure for the Company Patent and
Trademark Applications and has made no material misrepresentation in the Company Patent and Trademark Applications. To the Company&rsquo;s
knowledge, the Company Patent and Trademark Applications disclose patentable subject matter. The Company has not been notified of any
inventorship challenges nor has any interference been declared or provoked nor is any material fact known by the Company that would preclude
the issuance of patents with respect to the Company Patent and Trademark Applications or would render such patents, if issued, invalid
or unenforceable. Except as would not have a Material Adverse Effect, neither the Company nor any of its Subsidiaries has breached and
is currently in breach of any provision of any license, contract or other agreement governing the use by the Company or its Subsidiaries
of Intellectual Property owned by third parties (collectively, the &ldquo;<U>Licenses</U>&rdquo;) and no third party has alleged any such
breach and the Company is unaware of any facts that would form a reasonable basis for such a claim. To the Company&rsquo;s knowledge,
no other party to the Licenses has breached or is currently in breach of any provision of the Licenses. Each of the Licenses is in full
force and effect and constitutes a valid and binding agreement between the parties thereto, enforceable in accordance with its terms,
and there has not occurred any breach or default under any such Licenses or any event that, with the giving of notice or lapse of time,
would constitute a breach or default thereunder. Except as would not have a Material Adverse Effect, neither the Company nor any of its
Subsidiaries has been and is currently involved in any disputes regarding the Licenses. To the Company&rsquo;s knowledge, all patents
licensed to the Company pursuant to the Licenses are valid, enforceable and being duly maintained. To the Company&rsquo;s knowledge, all
patent applications licensed to the Company pursuant to the Licenses are being duly prosecuted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxviii)   <U>Environmental
Laws</U>. Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect: (i) neither
the Company nor any of its Subsidiaries is in violation of any United States federal, state or local, or any foreign, statute, law, rule,
regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial
or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including,
without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation,
laws and regulations relating to the emissions, discharges, release or threatened release of chemicals, pollutants, contaminants, wastes,
toxic substances, hazardous substances, petroleum or petroleum products (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) or otherwise
related to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials
(collectively, &ldquo;<U>Environmental Laws</U>&rdquo;), which violation includes, but is not limited to, noncompliance with any permits
or other governmental authorizations required for the operation of the business of the Company or any of its Subsidiaries under applicable
Environmental Laws, or noncompliance with the terms and conditions thereof, nor has the Company or any of its Subsidiaries received any
written communication, whether from a governmental authority, citizens group, employee or otherwise, that alleges that the Company or
any of its Subsidiaries is in violation of any Environmental Law; (ii) the Company and its Subsidiaries have all material permits, authorizations
and approvals required under any applicable Environmental Laws and are in compliance with their requirements; (iii) there are no pending
or, to the Company&rsquo;s knowledge, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims,
liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any
of its Subsidiaries, or any investigation with respect to which the Company or any of its Subsidiaries has received written notice or
any written notice by any person or entity alleging potential liability for investigatory costs, cleanup costs, governmental responses
costs, natural resources damages, property damages, personal injuries, attorneys&rsquo; fees or penalties arising out of, based on or
resulting from the presence, or release into the environment, of any Hazardous Materials at any location owned, leased or operated by
the Company or any of its Subsidiaries, now or in the past; and (iv) to the Company&rsquo;s knowledge, there are no past or present actions,
activities, events, conditions, incidents or circumstances that might reasonably be expected to result in a violation of any Environmental
Law or form the basis of an order for clean-up or remediation, or an action, suit, investigation or proceeding by any private party or
governmental body or agency, against or affecting the Company or any of its Subsidiaries relating to Hazardous Materials or any Environmental
Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxix)   <U>Books
and Records</U>. The Company and each of its Subsidiaries make and keep accurate books and records and maintain a system of internal accounting
controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&rsquo;s general
or specific authorization; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity
with GAAP and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management&rsquo;s general
or specific authorization; (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate
action is taken with respect to any differences; and (v) the interactive data in eXtensible Business Reporting Language included or incorporated
by reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly presents the information called for
in all material respects and is prepared in accordance with the Commission&rsquo;s rules and guidelines applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxx)   <U>Accounting
Controls and Disclosure Controls</U>. The Company and each of its Subsidiaries have established and maintain disclosure controls and procedures
(as defined in Rules 13a-15 and 15d-15 under the 1934 Act), which (i) are designed to ensure that information relating to the Company,
including its consolidated Subsidiaries, is made known to the Company&rsquo;s principal executive officer and its principal financial
officer by others within those entities, particularly during the periods in which the periodic reports required under the 1934 Act are
being prepared; (ii) have been evaluated by management of the Company for effectiveness as of the end of the Company&rsquo;s most recent
fiscal quarter; and (iii) are effective in all material respects to perform the functions for which they were established. Since the end
of the Company&rsquo;s most recent audited fiscal year, there has been no material weakness in the Company&rsquo;s internal control over
financial reporting (whether or not remediated) and no change in the Company&rsquo;s internal control over financial reporting, including
any corrective actions with regard to significant deficiencies or material weaknesses. The Company is not aware of any change in its internal
control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably
likely to materially affect, the Company&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxi)   <U>Tests
and Preclinical and Clinical Trials</U>. The research, non-clinical pre-clinical studies and clinical studies and tests conducted or being
conducted by or on behalf of the Company or any of its Subsidiaries or in which any of their respective product candidates have participated
and, to the Company&rsquo;s knowledge, the preclinical studies and clinical trials directed or sponsored by the Company&rsquo;s collaborators
(collectively, the &ldquo;<U>Studies</U>&rdquo;) that are described in, or the results of which are referred to in, the Registration Statement,
the General Disclosure Package and the Prospectus were and, if still pending, are being conducted with reasonable care and in all material
respects in accordance with the protocols, procedures and controls pursuant to all Applicable Laws and Governmental Permits and with standard
medical and scientific research procedure. Each description of the results of such Studies fairly presents in all material respects the
data derived from such Studies. The Company and its Subsidiaries have no knowledge of any other research, non-clinical studies or tests
the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration
Statement, the General Disclosure Package and the Prospectus. There have been no material serious adverse events resulting from any Study.
To the Company&rsquo;s knowledge, the manufacturing facilities and operations of its suppliers are operated in compliance in all material
respects with all Applicable Laws and Governmental Permits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxii)   <U>Payment
of Taxes</U>. All United States federal income tax returns of the Company and its Subsidiaries required by law to be filed have been filed
or extensions thereof have been requested (except in any case in which the failure to so file or request an extension would not have a
Material Adverse Effect), and all taxes shown by such returns or otherwise assessed, which are due and payable, have been paid, except
assessments that are being contested in good faith and as to which adequate reserves have been provided under GAAP and except for such
taxes the nonpayment of which would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.
The Company has no knowledge of any material tax deficiency which has been or is likely to be threatened or asserted against the Company
or its Subsidiaries. Each of the Company and its Subsidiaries has filed all foreign, state, provincial, local or other tax returns that
are required to have been filed pursuant to applicable foreign, state, provincial, local or other law except insofar as the failure to
file such returns would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, and paid
all taxes due pursuant to such returns or pursuant to any assessment received by the Company and its Subsidiaries, except for such taxes,
if any, as are being contested in good faith and as to which adequate reserves have been provided and except for such taxes or assessments
the nonpayment of which would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. The
charges, accruals and reserves on the books of the Company and its Subsidiaries in respect of any income or other tax liability for any
years not finally determined are adequate to meet any assessments or re-assessments for additional tax for any years not finally determined,
except to the extent of any inadequacy that would not reasonably be expected to result in a Material Adverse Effect. All material taxes
which the Company and its Subsidiaries are required by law to withhold or to collect for payment have been duly withheld and collected
and have been paid to the appropriate governmental authority or agency or have been accrued, reserved against and entered on the books
of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxiii)   <U>Insurance</U>.
Each of the Company and its Subsidiaries are insured by recognized and reputable institutions with policies in such amounts and with such
deductibles and covering such risks as are reasonably deemed adequate and customary for their businesses including, but not limited to,
policies covering real and personal property owned or leased by the Company and its Subsidiaries against theft, damage, destruction, acts
of vandalism and earthquakes and policies covering the Company and its Subsidiaries for clinical trial liability claims. The Company has
no reason to believe that it or any of its Subsidiaries will not be able (i) to renew its existing insurance coverage as and when such
policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business
as now conducted and at a cost that could not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of
its Subsidiaries has been denied any material insurance coverage which it has sought or for which it has applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxiv)   <U>Investment
Company Act</U>. The Company is not required, and upon the issuance and sale of the Securities as herein contemplated and the application
of the net proceeds therefrom as described in the Registration Statement, the General Disclosure Package and the Prospectus will not be
required, to register as an &ldquo;investment company&rdquo; under the Investment Company Act of 1940, as amended (the &ldquo;<U>1940
Act</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxv)   <U>Absence
of Manipulation</U>. Neither the Company, nor any of its Subsidiaries, nor to the knowledge of the Company, any of its or their respective
directors, officers or controlling persons has taken, directly or indirectly, without giving effect to any actions taken by the Underwriters,
(i) any action designed to or that might constitute or reasonably be expected to cause or result in, under the 1934 Act or otherwise,
stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities or (ii) any
action designed to or that might constitute or reasonably be expected to cause or result in a violation of Regulation M under the 1934
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxvi)   <U>Foreign
Corrupt Practices Act</U>. None of the Company, any Subsidiary, affiliate, director, officer or employee thereof or, to the Company&rsquo;s
knowledge, any agent, representative or other person acting on behalf of the Company or any of its Subsidiaries or affiliates, is aware
of or has taken any action, directly or indirectly, that would result in a violation by such persons of any applicable anti-corruption
laws, including the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the &ldquo;<U>FCPA</U>&rdquo;),
including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance
of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization
of the giving of anything of value to any &ldquo;foreign official&rdquo; (as such term is defined in the FCPA) or any foreign political
party or official thereof or any candidate for foreign political office or otherwise took any action (or failed to fully disclose any
action) in contravention of the FCPA; and the Company, its Subsidiaries and each of their respective affiliates have conducted their businesses
in compliance in all material respects with the FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxvii)
<U>Money Laundering Laws</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
in all material respects with applicable financial recordkeeping and reporting requirements and the money laundering statutes and the
rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any
governmental agency (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;) and no action, suit, investigation or proceeding by
or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its Subsidiaries with
respect to the Money Laundering Laws is pending or, to the Company&rsquo;s knowledge, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxviii)   <U>OFAC</U>.
Neither the Company nor any of its Subsidiaries, nor any director or officer thereof, nor, to the Company&rsquo;s knowledge, any employee,
agent, affiliate or representative of the Company or any of its Subsidiaries, is currently or is owned or controlled by an individual
or entity that is subject to any sanctions administered or enforced by the United States government (including, without limitation, the
Office of Foreign Assets Control of the United States Department of the Treasury), the United Nations Security Council, the European Union,
His Majesty&rsquo;s Treasury or other relevant sanctions authority (collectively, &ldquo;<U>Sanctions</U>&rdquo;) or is located, organized
or resident in a country or territory that is the subject or target of Sanctions; and the Company will not directly or indirectly use
the proceeds of the sale of the Securities, or lend, contribute or otherwise make available such proceeds to any Subsidiary, or any joint
venture partner or other person or entity, for the purpose of financing or facilitating the activities of or business of any person or
entity, or in any country or territory, that currently or at the time of such financing or facilitation is the subject of any Sanctions
or in any other manner that will result in a violation by any person or entity (including any person participating in the transactions
contemplated by this Agreement) of any Sanctions. For the past five years, the Company and its Subsidiaries have not knowingly engaged
in and are not now knowingly engaged in any dealings or transactions with any person or entity, or in any country or territory, that at
the time of the dealing or transaction is or was the subject of Sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xxxix)   <U>Lending
Relationship</U><I>. </I>Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company
(i)&nbsp;does not have any&nbsp;material lending or other relationship with any banking or lending affiliate of any Underwriter and (ii)&nbsp;does
not intend to use any of the proceeds from the sale of the Securities to repay any outstanding debt owed to any affiliate of any Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xl)   <U>Maintenance
of Rating</U>. The Company has no debt securities or preference shares that is rated by any &ldquo;nationally recognized statistical rating
organization&rdquo; (as that term is defined by the Commission for purposes of Rule 436(g)(2) under the 1933 Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xli)   <U>Privacy
and Data Protection</U>. To the Company&rsquo;s knowledge, the Company and its subsidiaries&rsquo; information technology assets and equipment,
computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &ldquo;<U>IT Systems</U>&rdquo;)
are adequate for, and operate and perform in all respects as required in connection with the operation of the business of the Company
and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware
and other corruptants, except as would not reasonably be expected to result in a Material Adverse Effect. The Company and its subsidiaries
have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards
to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all
IT Systems and data, including &ldquo;<U>Personal Data</U>,&rdquo; used in connection with their businesses. &ldquo;<U>Personal Data</U>&rdquo;
means (i) a natural person&rsquo;s name, street address, telephone number, e-mail address, photograph, social security number or tax identification
number, driver&rsquo;s license number, passport number, credit card number, bank information, or customer or account number; (ii) any
information which would qualify as &ldquo;personally identifying information&rdquo; under the Federal Trade Commission Act, as amended;
(iii) if applicable to the Company, &ldquo;personal data&rdquo; as defined by EU General Data Protection Regulation; (iv) if applicable
to the Company, any information which would qualify as &ldquo;protected health information&rdquo; under HIPAA; and (v) any other piece
of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any
data related to an identified person&rsquo;s health or sexual orientation. To the Company&rsquo;s knowledge, there have been no breaches,
violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability
or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and
its subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of
any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy
and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access,
misappropriation or modification, except where such failure to comply would not reasonably be expected to result in a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xlii)   <U>No
Broker Fees</U>. No person (as such term is defined in Rule 1-02 of Regulation S-X promulgated under the 1933 Act) has the right to act
as an underwriter or as a financial advisor to the Company in connection with the offer and sale of the Securities hereunder, whether
as a result of the filing or effectiveness of the Registration Statement or the sale of the Securities as contemplated hereby or otherwise.
Except for the Underwriters, there is no broker, finder or other party that is entitled to receive from the Company or any of its Subsidiaries
any brokerage or finder&rsquo;s fee or other fee or commission as a result of any transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xliii)   <U>No
Conflict</U>. Neither the execution and delivery by the Company of, nor the performance of the Company of its obligations under, this
Agreement will conflict with, result in a breach or violation of, or result in the creation or imposition of any lien, charge or encumbrance
upon any property or assets of the Company or any of its Subsidiaries pursuant to: (i) the Memorandum and Articles of Association, bylaws,
limited liability company agreement, certificate or agreement of limited or general partnership or other similar organizational documents,
as the case may be, of such entity, (ii) the terms of any indenture, contract, license, lease, mortgage, deed of trust, note agreement,
agreement or other instrument, obligation, condition, covenant or instrument to which it is a party or bound or to which its property
or assets is subject or (iii) any statute, law, rule, regulation, judgment, order or decree applicable to the Company or any of its Subsidiaries
of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Company,
any of its Subsidiaries or any of their respective properties or assets, as applicable, except, in the case of clauses (ii) and (iii)
above, for any such conflict, breach, violation or default that would not, individually or in the aggregate, have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xliv)   <U>Litigation</U>.
There are no actions, suits, claims, investigations or proceedings pending or, to the Company&rsquo;s knowledge, threatened to which the
Company or any of the Subsidiaries is or would be a party, or of which any of the respective properties or assets of the Company and the
Subsidiaries is or would be subject, at law or in equity, before any court or arbitral body or by or before any federal, state, local
or foreign governmental or regulatory commission, board, body, authority or agency, that (i) are required to be described in the Registration
Statement, the General Disclosure Package or the Prospectus and are not so described, (ii)&nbsp;could reasonably be expected to have a
material adverse effect on the ability of the Company to perform its obligations under this Agreement or on the consummation of any of
the transactions contemplated hereby or (iii) could reasonably be expected to have a Material Adverse Effect. The aggregate of all pending
legal or governmental proceedings to which the Company or any of its Subsidiaries is a party or of which any of their respective properties
or assets is the subject which are not described in the Prospectus, including ordinary routine litigation incidental to the Company&rsquo;s
business, could not reasonably be expected to (A) result in a Material Adverse Effect or (B) have a material adverse effect on the ability
of the Company to perform its obligations under this Agreement or the consummation of any of the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xlv)   <U>Real
Property</U>. The Company owns or leases all such real properties as are necessary to the conduct of its operations as presently conducted
in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xlvi)   <U>Transfer
Taxes</U>. There are no transfer taxes or other similar fees or charges under federal law, the laws of any state, any foreign law, or
any political subdivision thereof, required to be paid in connection with the execution and delivery of this Agreement or the issuance
or sale by the Company of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xlvii)   <U>ERISA</U>.
The Company and any &ldquo;employee benefit plan&rdquo; (as defined under the Employee Retirement Income Security Act of 1974, as amended,
and the regulations and published interpretations thereunder (collectively, &ldquo;<U>ERISA</U>&rdquo;)) established or maintained by
the Company, or its &ldquo;ERISA Affiliates&rdquo; (as defined below) are in compliance with ERISA, except as would not reasonably be
expected to have, individually or in the aggregate, a Material Adverse Effect. &ldquo;ERISA Affiliates&rdquo; means, with respect to the
Company, any member of any group of organizations described in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986,
as amended, and the regulations and published interpretations thereunder (the &ldquo;<U>Code</U>&rdquo;) of which the Company is a member.
No &ldquo;reportable event&rdquo; (as defined under ERISA) has occurred or is reasonably expected to occur with respect to any &ldquo;employee
benefit plan&rdquo; established or maintained by the Company, or any of its ERISA Affiliates. No &ldquo;employee benefit plan&rdquo; established
or maintained by the Company or any of its ERISA Affiliates, if such &ldquo;employee benefit plan&rdquo; were terminated, would have any
&ldquo;amount of unfunded benefit liabilities&rdquo; (as defined under ERISA). Neither the Company nor any of its ERISA Affiliates has
incurred or reasonably expects to incur any liability under (i) Title IV of ERISA with respect to termination of, or withdrawal from,
any &ldquo;employee benefit plan&rdquo; or (ii) Sections 412, 4971, 4975 or 4980B of the Code. Each &ldquo;employee benefit plan&rdquo;
established or maintained by the Company or any of its ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code
is so qualified and nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xlviii)   <U>Anti-Corruption</U>.
Neither the Company, any of its Subsidiaries, nor, to the knowledge of the Company, any of their respective directors, officers, agents,
employees or affiliates, has taken or will take any action in furtherance of an offer, payment, promise to pay, or authorization or approval
of the unlawful payment or giving of money, property, gifts or anything else of value, directly or indirectly, to any &ldquo;government
official&rdquo; (including any officer or employee of a government or government-owned or controlled entity or of a public international
organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official
or candidate for political office) to influence official action or secure an improper advantage; and the Company, each of its Subsidiaries
and, to the Company&rsquo;s knowledge, each of their respective affiliates have conducted their businesses in compliance with applicable
anti-corruption laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(xlix) <U>Broker-Dealer
Registration</U>. The Company is not required to register as a &ldquo;broker&rdquo; or &ldquo;dealer&rdquo; in accordance with the
provisions of the 1934 Act and does not, directly or indirectly through one or more intermediaries, control or have any other association
with (within the meaning of Article I of the By-laws of FINRA) any member firm of FINRA. No relationship, direct or indirect, exists between
or among the Company, on the one hand, and the directors, officers or shareholders of the Company, on the other hand, which is required
by the rules of FINRA to be described in the Registration Statement, the General Disclosure Package and the Prospectus, which is not so
described. All of the information (including, but not limited to, information regarding affiliations, security ownership and trading activity)
provided to the Underwriters or its counsel by the Company, its officers and directors and the holders of any securities (debt or equity)
or warrants, options or rights to acquire any securities of the Company in connection with the filing to be made and other supplemental
information to be provided to FINRA pursuant to FINRA Rule 5110 in connection with the transactions contemplated by this Agreement is
true, complete and correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l) <U>Margin
Rules</U>. Neither the issuance, sale and delivery of the Securities, nor the application of the proceeds thereof by the Company as
described in the Registration Statement, the General Disclosure Package and the Prospectus will violate Regulation T, U or X of the Board
of Governors of the Federal Reserve System or any other regulation of such Board of Governors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(li) <U>Director
Independence</U>. Each of the independent directors (or independent director nominees, once appointed, if applicable) named in the
Registration Statement, General Disclosure Package and Prospectus satisfies the independence standards established by Nasdaq and, with
respect to members of the Company&rsquo;s audit committee, the enhanced independence standards contained in Rule 10A-3(b)(1) promulgated
by the Commission under the 1934 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(lii) <U>Integration</U>. Neither
the Company nor, to the Company&rsquo;s knowledge, any of its affiliates (within the meaning of Rule 144 under the 1933 Act) has, prior
to the date hereof, made any offer or sale of any securities which could be &ldquo;integrated&rdquo; (within the meaning of the 1933 Act)
with the offer and sale of the Securities hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(liii) <U>Indebtedness</U>. Neither
the Company nor any of its Subsidiaries has (i) failed to pay any dividend or sinking fund installment on preference shares or (ii) defaulted
on any installment or payment due on indebtedness for borrowed money or on any rental on one or more long-term leases, which defaults,
individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(liv) <U>Forward
Looking Statements</U>. Each financial or operational projection or other &ldquo;forward-looking statement&rdquo; (as defined by Section
27A of the 1933 Act or Section 21E of the 1934 Act) contained in the Registration Statement, the General Disclosure Package or the Prospectus
(i) was so included by the Company in good faith and with reasonable basis after due consideration by the Company of the underlying assumptions,
estimates and other applicable facts and circumstances and (ii) as required, is accompanied by meaningful cautionary statements identifying
those factors that could cause actual results to differ materially from those in such forward-looking statement. No such statement was
made with the knowledge of a director or senior manager of the Company that was false or misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(lv) <U>Related
Party Transactions</U>. There are no relationships, direct or indirect, or related party transactions involving the Company or any
of its Subsidiaries or any other person (including any director, officer, shareholder, customer or supplier of the Company or any of its
Subsidiaries) required to be described in the Registration Statement, the General Disclosure Package or the Prospectus that have not been
described as required. There are no material outstanding loans, advances (except normal advances for business expenses in the ordinary
course of business) or guarantees of indebtedness by the Company or any of its Subsidiaries to or for the benefit of any of the officers
or directors of the Company or any of its Subsidiaries, or any of the family members of any of such persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(lvi) <U>Bankruptcy
and Insolvency</U>. The Company is not in or subject to a bankruptcy or insolvency proceeding in any jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(lvii) <U>Occupational
Laws</U>. The Company and its Subsidiaries (i) are in compliance, in all material respects, with any and all applicable foreign, federal,
state and local laws, rules, regulations, treaties, statutes and codes promulgated by any and all governmental authorities (including
pursuant to the Occupational Health and Safety Act) relating to the protection of human health and safety the workplace (&ldquo;<U>Occupational
Laws</U>&rdquo;); (ii) have received all material permits, licenses or other approvals required of it under applicable Occupational Laws
to conduct their respective businesses as currently conducted; and (iii) are in compliance, in all material respects, with all terms and
conditions of such permit, license or approval. No action, proceeding, revocation proceeding, writ, injunction or claim is pending or,
to the Company&rsquo;s knowledge, threatened against the Company or any of its Subsidiaries relating to Occupational Laws, and the Company
does not have knowledge of any facts, circumstances or developments relating to its operations or cost accounting practices that could
reasonably be expected to form the basis for or give rise to such actions, suits, investigations or proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(lviii) <U>Non-Competition
and Non-Competition Arrangements</U>. No director or officer of the Company or any of its Subsidiaries is subject to any non-competition
agreement or non-solicitation agreement with any employer or prior employer which could materially affect each director&rsquo;s or officer&rsquo;s
ability to be and act in the capacity of a director or officer of the Company or a Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(lix) <U>Choice
of Law</U>. The choice of laws of the State of New York as the governing law of this Agreement is a valid choice of law under the laws
of the Cayman Islands that will be honored by courts in the Cayman Islands. The Company has the power to submit to the non-exclusive personal
jurisdiction of the State of New York, and the Company has the power to designate, appoint and authorize an authorized agent for service
of process in any action arising out of or relating to this Agreement or the Securities in such courts in the State of New York, and service
of process effected on such authorized agent will be effective to confer valid personal jurisdiction over the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(lx) <U>Enforcement</U>. Any
final judgment for a fixed sum of money rendered by a court having jurisdiction under its own domestic laws in respect of any suit, action
or proceeding against the Company based upon this Agreement and the Securities would be recognized and enforced against the Company by
Cayman Islands courts without re-examining the merits of the case under the common law doctrine of obligation; provided that (i) adequate
service of process has been effected and the defendant has had a reasonable opportunity to be heard, (ii) such judgments or the enforcement
thereof are not contrary to the law, public policy, security or sovereignty of the Cayman Islands, (iii) such judgments were not obtained
by fraudulent means and do not conflict with any other valid judgment in the same matter between the same parties, and (iv) an action
between the same parties in the same matter is not pending in any Cayman Islands court at the time the lawsuit is instituted in the foreign
court; it is not necessary that this Agreement, the Prospectus or any other document be filed or recorded with any court or other authority
in the Cayman Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(lxi) <U>Transfer
Taxes</U>. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, no transaction stamp
or other issuance, transfer or withholding taxes or duties are payable by or on behalf of the Underwriters to the government of the Cayman
Islands or any political subdivision or taxing authority thereof or therein in connection with (i) the issuance of the Securities, (ii)
the sale and issuance by the Company of the Securities to or for the account of the Underwriters, (iii) the initial resale sale and issuance
by the Underwriters of the Securities to purchasers thereof or (iv) the execution, delivery and performance of this Agreement or any other
document contemplated hereby; provided, that, this Agreement is not executed in, or after execution, brought within the jurisdiction of
the Cayman Islands. The Company confirms it has not executed this Agreement in, nor will it, after execution, bring this Agreement within,
the jurisdiction of the Cayman Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)   <I>Officer&rsquo;s
Certificates</I>. Any certificate signed by any officer of the Company or any of its Subsidiaries delivered to the Representative or to
counsel for the Underwriters shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered
thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 2. <U>Sale and
Delivery to Underwriters; Closing</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)   <I>Securities</I>.
On the basis of the representations and warranties herein contained and subject to the terms and conditions herein set forth, the Company
agrees to sell to each Underwriter, severally and not jointly, and each Underwriter, severally and not jointly, agrees to purchase from
the Company, at the price per share set forth in <U>Schedule&nbsp;A</U>, that number of Securities set forth in <U>Schedule&nbsp;A</U>
opposite the name of such Underwriter, respectively, plus any additional number of Securities which such Underwriter may become obligated
to purchase pursuant to the provisions of Section 10 hereof, subject, in each case, to such adjustments among the Underwriters as the
Representative in its sole discretion shall make to eliminate any sales or purchases of fractional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)   [Reserved].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)   <I>Payment</I>.
Payment of the purchase price for, and delivery of certificates or security entitlements for, the Securities shall be made at the offices
of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., or at such other place as shall be agreed upon by the Representative and the Company,
at 10:00&nbsp;A.M. (New York City time) on the first (second, if the pricing occurs after 4:30 P.M. (New York City time) on any given
day) business day after the date hereof (unless postponed in accordance with the provisions of Section&nbsp;10), or such other time not
later than ten business days after such date as shall be agreed upon by the Representative and the Company (such time and date of payment
and delivery being herein called &ldquo;<U>Closing Time</U>&rdquo;). Delivery of the Securities at the Closing Time shall be made through
the facilities of The Depository Trust Company unless the Representative shall otherwise instruct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payment shall be made to the
Company by wire transfer of immediately available funds to a bank account designated by the Company, against delivery to the Representative
for the respective accounts of the Underwriters of certificates or security entitlements for the Securities to be purchased by them. It
is understood that each Underwriter has authorized the Representative, for its account, to accept delivery of, receipt for, and make payment
of the purchase price for, the Securities, which it has agreed to purchase. Leerink Partners, individually and not as representative of
the Underwriters, may (but shall not be obligated to) make payment of the purchase price for the Securities to be purchased by any Underwriter
whose funds have not been received by the Closing Time, but such payment shall not relieve such Underwriter from its obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 3. <U>Covenants
of the Company</U>. The Company covenants with each Underwriter as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)   <I>Compliance
with Securities Regulations and Commission Requests</I>. The Company, subject to Section 3(b), will comply with the requirements of Rule
430B, and will notify the Representative as soon as practicable, and confirm the notice in writing, (i) when any post-effective amendment
to the Registration Statement shall become effective or any amendment or supplement to the Prospectus shall have been filed, (ii)&nbsp;of
the receipt of any comments from the Commission, (iii)&nbsp;of any request by the Commission for any amendment to the Registration Statement
or any amendment or supplement to the Prospectus (including any document incorporated by reference therein) or for additional information,
(iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective
amendment or of any order preventing or suspending the use of any preliminary prospectus or the Prospectus, or of the suspension of the
qualification of the Securities for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any
of such purposes or of any examination pursuant to Section 8(d) or 8(e) of the 1933 Act concerning the Registration Statement and (v)
if the Company becomes the subject of a proceeding under Section 8A of the 1933 Act in connection with the offering of the Securities.
The Company will effect all filings required under Rule 424(b), in the manner and within the time period required by Rule 424(b) (without
reliance on Rule 424(b)(8)), and will take such steps as it deems necessary to ascertain promptly whether the form of prospectus transmitted
for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus.
The Company will make every reasonable effort to prevent the issuance of any stop order, prevention or suspension and, if any such order
is issued, to obtain the lifting thereof as soon as reasonably practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)   <I>Continued
Compliance with Securities Laws</I>. The Company will comply with the 1933 Act, the 1933 Act Regulations, the 1934 Act and the 1934 Act
Regulations so as to permit the completion of the distribution of the Securities as contemplated in this Agreement and in the Registration
Statement, the General Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Securities is (or, but
for the exception afforded by Rule 172 of the 1933 Act Regulations (&ldquo;<U>Rule 172</U>&rdquo;), would be) required by the 1933 Act
to be delivered in connection with sales of the Securities, any event shall occur or condition shall exist as a result of which it is
necessary, in the opinion of counsel for the Underwriters or for the Company, to (i)&nbsp;amend the Registration Statement in order that
the Registration Statement will not include an untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading, (ii) amend or supplement the General Disclosure Package or the Prospectus
in order that the General Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein not misleading in the light of the circumstances
existing at the time it is delivered to a purchaser or (iii) amend the Registration Statement or amend or supplement the General Disclosure
Package or the Prospectus, as the case may be, in order to comply with the requirements of the 1933 Act or the 1933 Act Regulations, the
Company will promptly (A) give the Representative notice of such event, (B) prepare any amendment or supplement as may be necessary to
correct such statement or omission or to make the Registration Statement, the General Disclosure Package or the Prospectus comply with
such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representative with copies of any
such amendment or supplement and (C) file with the Commission any such amendment or supplement; provided that the Company shall not file
or use any such amendment or supplement to which the Representative or counsel for the Underwriters shall reasonably object. The Company
will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters may reasonably request. The
Company has given the Representative notice of any filings made pursuant to the 1934 Act or the 1934 Act Regulations as soon as practicable
prior to the Applicable Time; the Company will give the Representative notice of its intention to make any such filing from the Applicable
Time to the Closing Time and will furnish the Representative with copies of any such documents a reasonable amount of time prior to such
proposed filing, as the case may be, and will not file or use any such document to which the Representative or counsel for the Underwriters
shall reasonably object.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)   <I>Delivery
of Registration Statements</I>. The Company has furnished or will deliver to the Representative and counsel for the Underwriters, without
charge, conformed copies of the Registration Statement as originally filed and each amendment thereto (including exhibits filed therewith
or incorporated by reference therein and documents incorporated or deemed incorporated by reference therein) and conformed copies of all
consents and certificates of experts. The copies of the Registration Statement and each amendment thereto furnished to the Underwriters
will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted
by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)   <I>Delivery
of Prospectuses</I>. The Company has delivered to each Underwriter, without charge, as many copies of each preliminary prospectus, if
any, as such Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted by the
1933 Act. The Company will furnish to each Underwriter, without charge, during the period when a prospectus relating to the Securities
is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, such number of copies of the
Prospectus (as amended or supplemented) as such Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto
furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to
EDGAR, except to the extent permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)   <I>Blue
Sky Qualifications</I>. The Company will use its reasonable best efforts, in cooperation with the Underwriters, to qualify the Securities
for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Representative
may designate and to maintain such qualifications in effect so long as required to complete the distribution of the Securities; provided,
however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation
or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing
business in any jurisdiction in which it is not otherwise so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)   <I>Rule
158</I>. The Company will timely file such reports pursuant to the 1934 Act as are necessary in order to make generally available (which
may be satisfied by filing with the Commission pursuant to EDGAR) to its securityholders as soon as practicable an earnings statement
for the purposes of, and to provide to the Underwriters the benefits contemplated by, the last paragraph of Section 11(a) of the 1933
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)   <I>Use
of Proceeds</I>. The Company will use the net proceeds received by it from the sale of the Securities in all material respects in the
manner specified in the Registration Statement, the General Disclosure Package and the Prospectus under the heading &ldquo;Use of Proceeds.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)   <I>Listing</I>.
The Company will use its reasonable best efforts to effect and maintain the listing of the Ordinary Shares (including the Securities)
on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)   <I>Restriction
on Sale of Securities</I>. During a period of 60 days from the date of the Prospectus, the Company will not, without the prior written
consent of the Representative, (i) directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any Ordinary
Shares or any securities convertible into or exercisable or exchangeable for Ordinary Shares or file or confidentially submit any registration
statement under the 1933 Act with respect to any of the foregoing, (ii)&nbsp;enter into any swap or any other agreement or any transaction
that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Ordinary Shares, whether any
such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of Ordinary Shares or such other securities,
in cash or otherwise or (iii) publicly announce an intention to effect any such swap, agreement or other transaction described in clauses
(i) and (ii). The foregoing sentence shall not apply to (A) the Securities to be sold hereunder; (B) any Ordinary Shares issued by the
Company upon the exercise of an option or warrant or the conversion of a convertible security outstanding on the date hereof and referred
to in the Registration Statement, the General Disclosure Package and the Prospectus; (C) any Ordinary Shares issued or options to purchase
Ordinary Shares granted pursuant to existing employee benefit plans of the Company referred to in the Registration Statement, the General
Disclosure Package and the Prospectus; (D) any Ordinary Shares issued pursuant to any existing non-employee director share plan or dividend
reinvestment plan referred to in the Registration Statement, the General Disclosure Package and the Prospectus; (E) the filing by the
Company of any registration statement on Form S-8 or a successor form thereto; (F) sales of Ordinary Shares pursuant to the Sales Agreement,
dated of August 31, 2023, by and between the Company and Leerink Partners or any replacement &ldquo;at the market offering&rdquo; program;
provided that in the case of clause (F), no such sales may be made until after 30 days from the date of this Agreement; or (G) the sale
or issuance of or entry into an agreement to sell or issue Ordinary Shares or other securities issued in connection with any (1) merger,
(2) acquisition of securities, businesses, properties or other assets, (3) joint venture or (4) strategic alliance or relationship, provided,
that the aggregate number of shares issued pursuant to this clause (G) shall not exceed 5.0% of the total number of outstanding Ordinary
Shares immediately following the issuance and sale of the Securities; provided further that the recipient of any such Ordinary Shares
or securities issued pursuant to this clause (G) during the 60-day restricted period shall enter into an agreement substantially in the
form of <U>Exhibit A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j)   <I>Reporting
Requirements</I>. The Company, during the period when a Prospectus relating to the Securities is (or, but for the exception afforded by
Rule 172, would be) required to be delivered under the 1933 Act, will file all documents required to be filed with the Commission pursuant
to the 1934 Act within the time periods required by the 1934 Act and 1934 Act Regulations. Additionally, the Company shall report the
use of proceeds from the issuance of the Securities as may be required under Rule 463 under the 1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k)   [Reserved].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l)   <I>Testing-the-Waters
Materials</I>. If at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs an event
or development as a result of which such Written Testing-the-Waters Communication included or would include an untrue statement of a material
fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
existing at that subsequent time, not misleading, the Company will promptly notify the Representative and will promptly amend or supplement,
at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such untrue statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(m)   <U>[</U>Reserved<U>]</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 4. <U>Payment of
Expenses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)   <I>Expenses</I>.
The Company will pay or cause to be paid all expenses incident to the performance of its obligations under this Agreement, including (i)
the preparation, printing and filing of the Registration Statement (including financial statements and exhibits) as originally filed and
each amendment thereto, (ii)&nbsp;the preparation, printing and delivery to the Underwriters of copies of any preliminary prospectus,
any Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements thereto and any costs associated with electronic
delivery of any of the foregoing by the Underwriters to investors, (iii) the preparation, issuance and delivery of the certificates or
security entitlements for the Securities to the Underwriters, including any share or other transfer taxes and any stamp or other duties
payable upon the sale, issuance or delivery of the Securities to the Underwriters, (iv)&nbsp;the fees and disbursements of the Company&rsquo;s
counsel, accountants and other advisors, (v)&nbsp;the qualification of the Securities under securities laws in accordance with the provisions
of Section&nbsp;3(e) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Underwriters in connection
therewith and in connection with the preparation of a &ldquo;Blue Sky Survey&rdquo; and any supplement thereto, (vi) the fees and expenses
of any transfer agent or registrar for the Securities, (vii) the costs and expenses of the Company relating to investor presentations
on any &ldquo;road show&rdquo; undertaken in connection with the marketing of the Securities, including without limitation, expenses associated
with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations,
travel and lodging expenses of the representatives and officers of the Company and any such consultants, and the cost of aircraft and
other transportation chartered in connection with the road show, (viii) the filing fees incident to, and the reasonable fees and disbursements
of counsel to the Underwriters in connection with, the review by FINRA of the terms of the sale of the Securities, with such legal fees,
taken together with the legal fees described in clause (v) above, not to exceed $20,000, (ix) the fees and expenses incurred in connection
with the listing of the Securities on Nasdaq, and (x) the costs and expenses (including, without limitation, any damages or other amounts
payable in connection with legal or contractual liability) associated with the reforming of any contracts for sale of the Securities made
by the Underwriters caused by a breach of the representation contained in the third sentence of Section 1(a)(ii). Except as provided in
this Section 4, the Underwriters will pay all of their own costs and expenses, including the fees and disbursements of their counsel,
stock transfer taxes payable on the resale of any of the Securities by them and any advertising expenses connected with any offers they
may make.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)   <I>Termination
of Agreement</I>. If this Agreement is terminated by the Representative in accordance with the provisions of Section&nbsp;5, Section&nbsp;9(a)(i),
Section 9(a)(iii) or Section 10 hereof, the Company shall reimburse the non-defaulting Underwriters for all of their reasonable documented
out-of-pocket expenses actually incurred, including the reasonable fees and disbursements of counsel for the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 5. <U>Conditions
of Underwriters&rsquo; Obligations</U>. The obligations of the several Underwriters hereunder are subject to the accuracy of the representations
and warranties of the Company contained herein or in certificates of any officer of the Company or any of its Subsidiaries delivered pursuant
to the provisions hereof, to the performance by the Company of its covenants and other obligations hereunder, and to the following further
conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)   <I>Effectiveness
of Registration Statement</I>. The Registration Statement, including any Rule 462(b) Registration Statement, has become effective and,
at the Closing Time, no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto
has been issued under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been
issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company&rsquo;s knowledge, contemplated;
and the Company has complied with each request (if any) from the Commission for additional information to the reasonable satisfaction
of counsel to the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)   <I>Opinions
of Counsel for Company</I>. At the Closing Time, the Representative shall have received (i) the opinion and the negative assurance letter,
each dated the Closing Time, of Gibson, Dunn &amp; Crutcher LLP, counsel for the Company, (ii) the opinion of Walkers (Cayman) LLP, counsel
for the Company as to certain matters of Cayman Islands law, and (iii) the opinion of Greenblum &amp; Bernstein, P.L.C., special counsel
for the Company with respect to intellectual property matters, each in form and substance satisfactory to counsel for the Underwriters
and to such further effect as counsel to the Underwriters may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)   <I>Opinion
of Counsel for Underwriters</I>. At the Closing Time, the Representative shall have received the opinion, and negative assurance letter,
each dated the Closing Time, of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel for the Underwriters, together with signed
or reproduced copies of such letters for each of the other Underwriters in form and substance satisfactory to the Representative. In giving
such opinion such counsel may rely, as to all matters governed by the laws of jurisdictions other than the law of the State of New York
and the federal securities laws of the United States, upon the opinions of counsel satisfactory to the Representative. Such counsel may
also state that, insofar as such opinion involves factual matters, they have relied, to the extent they deem proper, upon certificates
of officers and other representatives of the Company and its Subsidiaries and certificates of public officials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)   <I>Officers&rsquo;
Certificate</I>. At the Closing Time, there shall not have been, since the date hereof or since the respective dates as of which information
is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse change in the condition,
financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its Subsidiaries considered as one
enterprise, whether or not arising in the ordinary course of business, and the Representative shall have received a certificate of the
principal executive officer of the Company and of the principal financial officer of the Company, dated the Closing Time, to the effect
that (i) there has been no such material adverse change, (ii)&nbsp;the representations and warranties of the Company in this Agreement
are true and correct with the same force and effect as though expressly made at and as of the Closing Time, (iii)&nbsp;the Company has
complied in all material respects with all agreements and satisfied all conditions on its part to be performed or satisfied at or prior
to the Closing Time, and (iv)&nbsp;no stop order suspending the effectiveness of the Registration Statement under the 1933 Act has been
issued, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for
any of those purposes have been instituted or are pending or, to their knowledge, contemplated by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)   <I>Accountant&rsquo;s
Comfort Letter</I>. At the time of the execution of this Agreement, the Representative shall have received from Baker Tilly US, LLP a
letter, dated such date, in form and substance satisfactory to the Representative, together with signed or reproduced copies of such letter
for each of the other Underwriters containing statements and information of the type ordinarily included in accountants&rsquo; &ldquo;comfort
letters&rdquo; to underwriters with respect to the financial statements and certain financial information contained in the Registration
Statement, the General Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)   <I>Bring-down
Comfort Letter</I>. At the Closing Time, the Representative shall have received from Baker Tilly US, LLP a letter, dated as of the Closing
Time, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection (e) of this Section, except
that the specified date referred to shall be a date not more than three business days prior to the Closing Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)   <I>Approval
of Listing</I>. At the Closing Time, the Nasdaq Stock Market LLC shall not have raised any objection to the listing of the Securities
on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)   <I>No
Objection</I>. FINRA has confirmed that it has not raised any objection with respect to the fairness and reasonableness of the underwriting
terms and arrangements relating to the offering of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)   <I>Lock-up
Agreements</I>. At the date of this Agreement, the Representative shall have received an agreement substantially in the form of <U>Exhibit&nbsp;A</U>
hereto signed by each of the Company&rsquo;s directors and officers and their respective affiliated securityholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j)   <I>Chief
Financial Officer&rsquo;s Certificate.</I> On the date of this Agreement and at the Closing Time, the Representative shall have received
from the Company a certificate of its principal financial officer with respect to certain financial data contained in the General Disclosure
Package and the Prospectus, which certificate shall be substantially in the form reasonably satisfactory to the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k)   <I>Maintenance
of Rating</I>. Neither the Company nor its subsidiaries have any debt securities or preference shares that are rated by any &ldquo;nationally
recognized statistical rating agency&rdquo; (as defined in Section 3(a)(62) of the 1934 Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l)   [Reserved].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(m)   <I>Additional
Documents</I>. At the Closing Time, counsel for the Underwriters shall have been furnished with such other documents and opinions as they
may reasonably require for the purpose of enabling them to pass upon the issuance and sale of the Securities as herein contemplated, or
in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions, herein contained;
and all proceedings taken by the Company in connection with the issuance and sale of the Securities as herein contemplated shall be reasonably
satisfactory in form and substance to the Representative and counsel for the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(n)   <I>Termination
of Agreement</I>. If any condition specified in this Section shall not have been fulfilled when and as required to be fulfilled, this
Agreement may be terminated by the Representative by notice to the Company at any time at or prior to Closing Time, and such termination
shall be without liability of any party to any other party except as provided in Section 4 and except that Sections 1, 4, 6, 7, 8, 14,
15, 16 and 17 shall survive any such termination and remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 6. <U>Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)   <I>Indemnification
of Underwriters</I>. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates (as such term is defined in Rule
501(b) under the 1933 Act (each, an &ldquo;<U>Affiliate</U>&rdquo;)), its selling agents and each person, if any, who controls any Underwriter
within the meaning of Section&nbsp;15 of the 1933 Act or Section 20 of the 1934 Act as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)   against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement or alleged untrue
statement of a material fact contained in the Registration Statement (or any amendment thereto), including any information deemed to be
a part thereof pursuant to Rule 430B, or the omission or alleged omission therefrom of a material fact required to be stated therein or
necessary to make the statements therein not misleading or arising out of any untrue statement or alleged untrue statement of a material
fact included (A) in any preliminary prospectus, any Issuer Free Writing Prospectus, any Written Testing-the-Waters Communication, the
General Disclosure Package or the Prospectus (or any amendment or supplement thereto), or (B) in any materials or information provided
to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Securities (&ldquo;<U>Marketing
Materials</U>&rdquo;), including any roadshow or investor presentations made to investors by the Company (whether in person or electronically),
or the omission or alleged omission in any preliminary prospectus, any Issuer Free Writing Prospectus, any Written Testing-the-Waters
Communication, the General Disclosure Package, the Prospectus (or any amendment or supplement thereto) or in any Marketing Materials of
a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)   against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement
of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever
based upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided that (subject to Section
6(d) below) any such settlement is effected with the written consent of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)   against
any and all expense whatsoever, as incurred (including the fees and disbursements of counsel chosen by the Representative), reasonably
incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency
or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue
statement or omission, to the extent that any such expense is not paid under (i) or (ii) above;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">provided, however, that this
indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue statement
or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including any information
deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto)
in reliance upon and in conformity with the Underwriter Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)   <I>Indemnification
of Company, Directors and Officers</I>. Each Underwriter severally agrees to indemnify and hold harmless the Company, its directors, each
of its officers who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section
15 of the 1933 Act or Section 20 of the 1934 Act, against any and all loss, liability, claim, damage and expense described in the indemnity
contained in subsection (a) of this Section, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements
or omissions, made in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant
to Rule 430B, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity
with the Underwriter Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)   <I>Actions
against Parties; Notification</I>. Each indemnified party shall give notice as promptly as reasonably practicable to each indemnifying
party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying
party shall not relieve such indemnifying party from any liability hereunder to the extent it is not materially prejudiced as a result
thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement.
In the case of parties indemnified pursuant to Section 6(a) above, counsel to the indemnified parties shall be selected by the Representative,
and, in the case of parties indemnified pursuant to Section 6(b) above, counsel to the indemnified parties shall be selected by the Company.
An indemnifying party may participate at its own expense in the defense of any such action; provided, however, that counsel to the indemnifying
party shall not (except with the consent of the indemnified party) also be counsel to the indemnified party. In no event shall the indemnifying
parties be liable for the reasonable fees and expenses of more than one counsel (in addition to any local counsel) separate from their
own counsel for all indemnified parties in connection with any one action or separate but similar or related actions in the same jurisdiction
arising out of the same general allegations or circumstances. No indemnifying party shall, without the prior written consent of the indemnified
parties, settle or compromise or consent to the entry of any judgment with respect to any litigation, or any investigation or proceeding
by any governmental agency or body, commenced or threatened, or any claim whatsoever in respect of which indemnification or contribution
could be sought under this Section 6 or Section 7 hereof (whether or not the indemnified parties are actual or potential parties thereto),
unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified party from all liability arising
out of such litigation, investigation, proceeding or claim and (ii) does not include a statement as to or an admission of fault, culpability
or a failure to act by or on behalf of any indemnified party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)   <I>Settlement
without Consent if Failure to Reimburse</I>. If at any time an indemnified party shall have requested an indemnifying party to reimburse
the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the
nature contemplated by Section 6(a)(ii) effected without its written consent if (i) such settlement is entered into more than 45 days
after receipt by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall have received notice of the terms
of such settlement at least 30 days prior to such settlement being entered into and (iii) such indemnifying party shall not have reimbursed
such indemnified party in accordance with such request prior to the date of such settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 7. <U>Contribution</U>.
If the indemnification provided for in Section&nbsp;6 hereof is for any reason unavailable to or insufficient to hold harmless an indemnified
party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute
to the aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such indemnified party, as incurred, (i)
in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters,
on the other hand, from the offering of the Securities pursuant to this Agreement or (ii) if the allocation provided by clause (i) is
not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause
(i) above but also the relative fault of the Company, on the one hand, and of the Underwriters, on the other hand, in connection with
the statements or omissions which resulted in such losses, liabilities, claims, damages or expenses, as well as any other relevant equitable
considerations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The relative benefits received
by the Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Securities pursuant to
this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Securities
pursuant to this Agreement (after deducting underwriting discounts and commissions but before deducting expenses) received by the Company,
on the one hand, and the total underwriting discount received by the Underwriters, on the other hand, in each case as set forth on the
cover of the Prospectus, bear to the aggregate initial offering price of the Securities as set forth on the cover of the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The relative fault of the
Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any
such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information
supplied by the Company or by the Underwriters and the parties&rsquo; relative intent, knowledge, access to information and opportunity
to correct or prevent such statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and the Underwriters
agree that it would not be just and equitable if contribution pursuant to this Section 7 were determined by pro rata allocation (even
if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the
equitable considerations referred to above in this Section 7. The aggregate amount of losses, liabilities, claims, damages and expenses
incurred by an indemnified party and referred to above in this Section 7 shall be deemed to include any legal or other expenses reasonably
incurred by such indemnified party in investigating, preparing or defending against any litigation, or any investigation or proceeding
by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement
or omission or alleged omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the provisions
of this Section 7, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions received
by such Underwriter in connection with the Securities underwritten by it and distributed to the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the 1933 Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this Section
7, each person, if any, who controls an Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act and
each Underwriter&rsquo;s Affiliates and selling agents shall have the same rights to contribution as such Underwriter, and each director
of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within
the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act shall have the same rights to contribution as the Company. The
Underwriters&rsquo; respective obligations to contribute pursuant to this Section 7 are several in proportion to the number of Securities
set forth opposite their respective names in <U>Schedule&nbsp;A</U> hereto and not joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 8. <U>Representations,
Warranties and Agreements to Survive</U>. All representations, warranties and agreements contained in this Agreement or in certificates
of officers of the Company or any of its Subsidiaries submitted pursuant hereto, shall remain operative and in full force and effect regardless
of (i) any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter,
its officers or directors or any person controlling the Company and (ii) delivery of and payment for the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 9. <U>Termination
of Agreement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)   <I>Termination</I>.
The Representative may terminate this Agreement, by notice to the Company, at any time at or prior to the Closing Time (i) if there has
been, in the judgment of the Representative, since the time of execution of this Agreement or since the respective dates as of which information
is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse change in the condition,
financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its Subsidiaries considered as one
enterprise, whether or not arising in the ordinary course of business, or (ii)&nbsp;if there has occurred any material adverse change
in the financial markets in the United States or the international financial markets, any outbreak of hostilities or escalation thereof
or other calamity or crisis or any change or development involving a prospective change in U.S. or international political, financial
or economic conditions, in each case the effect of which is such as to make it, in the judgment of the Representative, impracticable or
inadvisable to proceed with the completion of the offering or to enforce contracts for the sale of the Securities, or (iii)&nbsp;if trading
in any securities of the Company has been suspended or materially limited by the Commission or Nasdaq, or (iv) if trading generally on
the NYSE MKT or the New York Stock Exchange or in the Nasdaq Stock Market has been suspended or materially limited, or minimum or maximum
prices for trading have been fixed, or maximum ranges for prices have been required, by any of said exchanges or by order of the Commission,
FINRA or any other governmental authority, (v)&nbsp;a material disruption has occurred in commercial banking or securities settlement
or clearance services in the United States or with respect to Clearstream or Euroclear systems in Europe, or (vi) if a banking moratorium
has been declared by either Federal or New York authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)   <I>Liabilities</I>.
If this Agreement is terminated pursuant to this Section, such termination shall be without liability of any party to any other party
except as provided in Section 4 hereof, and provided further that Sections 1, 4, 6, 7, 8, 14, 15, 16 and 17 shall survive such termination
and remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 10. <U>Default
by One or More of the Underwriters</U>. If one or more of the Underwriters shall fail at the Closing Time to purchase the Securities which
it or they are obligated to purchase under this Agreement (the &ldquo;<U>Defaulted Securities</U>&rdquo;), the Representative shall have
the right, within 24&nbsp;hours thereafter, to make arrangements for one or more of the non-defaulting Underwriters, or any other underwriters,
to purchase all, but not less than all, of the Defaulted Securities in such amounts as may be agreed upon and upon the terms herein set
forth; if, however, the Representative shall not have completed such arrangements within such 24-hour period, then:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)   if
the number of Defaulted Securities does not exceed 10% of the number of Securities to be purchased on such date, each of the non-defaulting
Underwriters shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions that their respective
underwriting obligations hereunder bear to the underwriting obligations of all non-defaulting Underwriters, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)   if
the number of Defaulted Securities exceeds 10% of the number of Securities to be purchased on such date, this Agreement shall terminate
without liability on the part of any non-defaulting Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No action taken pursuant to
this Section shall relieve any defaulting Underwriter from liability in respect of its default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of any such default
which does not result in a termination of this Agreement, either the (i) Representative or (ii) the Company shall have the right to postpone
Closing Time, for a period not exceeding seven days in order to effect any required changes in the Registration Statement, the General
Disclosure Package or the Prospectus or in any other documents or arrangements. As used herein, the term &ldquo;Underwriter&rdquo; includes
any person substituted for an Underwriter under this Section 10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 11. <U>Notices</U>.
All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted
by any standard form of telecommunication. Notices to the Underwriters shall be directed (i) to Leerink Partners LLC at 1301 Avenue of
the Americas, 5<SUP>th</SUP> Floor, New York, New York, 10019, attention of Stuart R. Nayman and (ii) to Mintz, Levin, Cohn, Ferris, Glovsky
at Popeo, P.C. at One Financial Center, Boston, MA 02111, attention of William C. Hicks, John T. Rudy, and Nishant M. Dharia. Notices
to the Company shall be directed to (i) MoonLake Immunotherapeutics, Dorfstrasse 29, 6300 Zug, Switzerland, Attention: Chief Financial
Officer and (ii) Gibson, Dunn &amp; Crutcher LLP, One Embarcadero Center, Suite 2600, San Francisco, CA 94111, Attention: Ryan A. Murr
and Branden Berns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 12. <U>No Advisory
or Fiduciary Relationship</U>. The Company acknowledges and agrees that (a) the purchase and sale of the Securities pursuant to this Agreement,
including the determination of the initial offering price of the Securities and any related discounts and commissions, is an arm&rsquo;s-length
commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b) in connection with the
offering of the Securities and the process leading thereto, each Underwriter is and has been acting solely as a principal and is not the
agent or fiduciary of the Company, any of its Subsidiaries or their respective shareholders, creditors, employees or any other party,
(c) no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering
of the Securities or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company
or any of its Subsidiaries on other matters) and no Underwriter has any obligation to the Company with respect to the offering of the
Securities except the obligations expressly set forth in this Agreement, (d) the Underwriters and their respective affiliates may be engaged
in a broad range of transactions that involve interests that differ from those of the Company and (e) the Underwriters have not provided
any legal, accounting, regulatory or tax advice with respect to the offering of the Securities and the Company has consulted its own respective
legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 13. <U>Recognition
of the U.S. Special Resolution Regimes</U>. In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding
under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under
this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this
Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that any Underwriter
that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime,
Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent
than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the
United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this Agreement,
(A) &ldquo;BHC Act Affiliate&rdquo; has the meaning assigned to the term &ldquo;affiliate&rdquo; in, and shall be interpreted in accordance
with, 12 U.S.C. &sect; 1841(k); (B) &ldquo;Covered Entity&rdquo; means any of the following: (i) a &ldquo;covered entity&rdquo; as that
term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b); (ii) a &ldquo;covered bank&rdquo; as that term is
defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or (iii) a &ldquo;covered FSI&rdquo; as that term is defined
in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b); (C) &ldquo;Default Right&rdquo; has the meaning assigned to that term
in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as applicable; and (D) &ldquo;U.S. Special
Resolution Regime&rdquo; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title
II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 14. <U>Parties</U>.
This Agreement shall each inure to the benefit of and be binding upon the Underwriters and the Company and their respective successors.
Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or corporation, other than
the Underwriters and the Company and their respective successors and the controlling persons and officers and directors referred to in
Sections&nbsp;6 and 7 and their heirs and legal representatives, any legal or equitable right, remedy or claim under or in respect of
this Agreement or any provision herein contained. This Agreement and all conditions and provisions hereof are intended to be for the sole
and exclusive benefit of the Underwriters and the Company and their respective successors, and said controlling persons and officers and
directors and their heirs and legal representatives, and for the benefit of no other person, firm or corporation. No purchaser of Securities
from any Underwriter shall be deemed to be a successor by reason merely of such purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 15. <U>Waiver of
Trial by Jury</U>. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its shareholders and affiliates)
and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial
by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 16. <U>GOVERNING
LAW</U>. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED
IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 17. <U>Consent
to Jurisdiction; Waiver of Immunity</U>. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions
contemplated hereby shall&nbsp;be instituted in (i) the federal courts of the United States of America located in the City and County
of New York, Borough of Manhattan or&nbsp;(ii) the courts of the State of New York located in the City and County of New York, Borough
of Manhattan (collectively, the &ldquo;<U>Specified Courts</U>&rdquo;), and each party irrevocably submits to the exclusive jurisdiction
(except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such jurisdiction is non-exclusive)
of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party&rsquo;s
address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The
parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified
Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other
proceeding brought in any such court has been brought in an inconvenient forum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 18. <U>TIME</U>.
TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 19. <U>Partial
Unenforceability</U>. The invalidity or unenforceability of any Section, paragraph or provision of this Agreement shall not affect the
validity or enforceability of any other Section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement
is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor
changes) as are necessary to make it valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 20. <U>Counterparts</U>.
This Agreement may be executed in any number of counterparts (which may include counterparts delivered by any standard form of telecommunication),
each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same agreement. Counterparts
may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform
Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission
method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 21. <U>Effect of
Headings</U>. The Section headings herein are for convenience only and shall not affect the construction hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SECTION
22. <U>Entire Agreement</U>. This Agreement supersedes all prior agreements and understandings (whether written or oral) between the
Company and the Underwriters, or any of them, with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGES FOLLOW]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing is in accordance
with your understanding of our agreement, please sign and return to the Company a counterpart hereof, whereupon this instrument, along
with all counterparts, will become a binding agreement between the Underwriter and the Company in accordance with its terms.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">MOONLAKE IMMUNOTHERAPEUTICS</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>By:</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Matthias Bodenstedt</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%">&nbsp;</TD>
  <TD STYLE="width: 3%">&nbsp;</TD>
  <TD STYLE="width: 5%">Name:</TD>
  <TD STYLE="width: 32%">Matthias Bodenstedt</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD>Chief Financial Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3">CONFIRMED AND ACCEPTED</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3" STYLE="padding-left: 0.125in">As of the date first above written:</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3">LEERINK PARTNERS LLC</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>By: </TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Sean Pitt </TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 4%">&nbsp;</TD>
  <TD STYLE="width: 5%">Name:</TD>
  <TD STYLE="width: 31%">Sean Pitt</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD>Senior Managing Director</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For themselves and as Representative of the other Underwriters named
in <U>Schedule&nbsp;A</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">[signature Page to Underwriting Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The initial offering price per share for the Securities shall be $10.50.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The purchase price per share for the Securities to be paid by the several
Underwriters shall be $10.185, being an amount equal to the initial offering price set forth above less $0.315 per share, subject to adjustment
in accordance with Section 2(b) for dividends or distributions declared by the Company and payable on the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">Name of Underwriter</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">Number of<BR> <U STYLE="text-decoration: none">Securities</U></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; padding-bottom: 1.5pt">Leerink Partners LLC</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">7,142,857</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,142,857</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE B-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Pricing Terms</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">The Company is selling 7,142,857 Ordinary Shares.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">The initial offering price per share for the Securities shall
be $10.50.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE B-2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>List of Written Testing-the-Waters Communications</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF LOCK-UP AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">November __, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leerink Partners LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">as Representative of the several Underwriters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">c/o</TD><TD STYLE="text-align: justify">Leerink Partners LLC</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">53 State Street, 40th Floor</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Boston, MA 02109</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">Re:</TD><TD STYLE="text-align: justify"><U>Proposed Public Offering by MoonLake Immunotherapeutics</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned, a shareholder,
officer and/or director of MoonLake Immunotherapeutics, a Cayman Islands exempted company (the &ldquo;<U>Company</U>&rdquo;), understands
that Leerink Partners LLC (the &ldquo;<U>Representative</U>&rdquo;) proposes to enter into an Underwriting Agreement (the &ldquo;<U>Underwriting
Agreement</U>&rdquo;) with the Company providing for the public offering (the &ldquo;<U>Public Offering</U>&rdquo;) of the Company&rsquo;s
Class A ordinary shares, par value $0.0001 per share (the &ldquo;<U>Shares</U>&rdquo;), and any other securities as may be determined
to be issued by the Company pursuant to the Underwriting Agreement. In recognition of the benefit that such an offering will confer upon
the undersigned as a shareholder, an officer and/or a director of the Company, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the undersigned agrees with each underwriter to be named in the Underwriting Agreement
(collectively, the &ldquo;<U>Underwriters</U>&rdquo;) that, during the period beginning on the date hereof and ending on the date that
is 60 days from the date of the Underwriting Agreement (the &ldquo;<U>Lock-Up Period</U>&rdquo;), the undersigned will not, without the
prior written consent of the Representative, on behalf of the Underwriters, directly or indirectly, (i) offer, pledge, sell, contract
to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the
sale of, or otherwise dispose of or transfer any Shares or any securities convertible into or exchangeable or exercisable for Shares,
whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power
of disposition (collectively, the &ldquo;<U>Lock-Up Securities</U>&rdquo;), or exercise any right with respect to the registration of
any of the Lock-Up Securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act
of 1933, as amended, or (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly
or indirectly, the economic consequence of ownership of the Lock-Up Securities, whether any such swap or transaction is to be settled
by delivery of Shares or other securities, in cash or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
and subject to the conditions below, the undersigned may transfer Lock-Up Securities without the prior written consent of the Representative,
provided, in each case, that (1)&nbsp;in the cases of (i), (ii), (iii), (iv), (v), (ix) and (x), the Representative receives a signed
lock-up agreement for the balance of the Lock-Up Period from each donee, trustee, distributee, or transferee, as the case may be, (2)
any such transfer shall not involve a disposition for value, (3) such transfers are not required to be reported with the Securities and
Exchange Commission on Form 4 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange
Act</U>&rdquo;), and (4) the undersigned does not otherwise voluntarily effect any public filing or report regarding such transfers (other
than a filing on a Form 5 made after the expiration of the Lock-Up Period):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">as a <I>bona fide</I> gift or gifts or for <I>bona fide</I> estate planning purposes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">to any member of the immediate family of the undersigned or any trust for the direct or indirect benefit
of the undersigned or the immediate family of the undersigned (for purposes of this lock-up agreement, &ldquo;immediate family&rdquo;
shall mean any relationship by blood, marriage or adoption, not more remote than first cousin);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">as a distribution or other transfer by a partnership to its partners or former partners or by a limited
liability company to its members or former members, or by a corporation to its shareholders or former shareholders or to any wholly-owned
subsidiary of such corporation, or by a trust contemplated in clause (ii) above to its beneficiaries;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">to the undersigned&rsquo;s affiliates or to any investment fund or other entity controlled or managed
by the undersigned or the immediate family of the undersigned;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">pursuant to a qualified domestic relations order or in connection with a divorce settlement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">by will, other testamentary document or intestate succession upon the death of the undersigned;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD STYLE="text-align: justify">to the Company in satisfaction of any tax withholding obligation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(viii)</TD><TD STYLE="text-align: justify">in connection with the conversion of any convertible security into, or the exercise of any option or warrant
for, Shares in a manner consistent with the description of such securities contained in the Prospectus, provided that any such Shares
received shall be subject to the terms of this agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ix)</TD><TD STYLE="text-align: justify">to a charitable organization or educational institution; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(x)</TD><TD STYLE="text-align: justify">to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible
under clauses (i) through (ix) above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, no provision
in this letter shall be deemed to restrict or prohibit (1) the transfer of the undersigned&rsquo;s Lock-Up Securities to the Company in
connection with the termination of the undersigned&rsquo;s services to the Company, provided that any filing under Section 16 of the Exchange
Act made in connection with such transfer shall clearly indicate in the footnotes thereto that the filing relates to the circumstances
described in this clause (1); (2) the exercise or exchange by the undersigned of any option or warrant to acquire any Shares or options
to purchase Shares, in each case for cash or on a &ldquo;cashless&rdquo; or &ldquo;net exercise&rdquo; basis, pursuant to any share option,
share bonus or other share plan or arrangement; provided, however, that the underlying Shares shall continue to be subject to the restrictions
on transfer set forth in this letter and that any filing under Section 16 of the Exchange Act made in connection with such exercise or
exchange shall clearly indicate in the footnotes thereto that (a) the filing relates to the circumstances described in this clause (2)
and (b) no shares were sold by the reporting person; (3) the transfer of Lock-Up Securities upon the completion of a bona fide third-party
tender offer, merger, consolidation or other similar transaction made to all holders of the Company&rsquo;s securities involving a change
of control of the Company (including, without limitation, the entering into of any lock-up, voting or similar agreement pursuant to which
the undersigned may agree to transfer, sell, tender or otherwise dispose of Shares or other such securities in connection with such transaction,
or vote any Shares or other securities in favor of any such transaction); provided, however, that in the event that such tender offer,
merger, consolidation or other such transaction is not completed, such securities held by the undersigned shall remain subject to the
restrictions on transfer set forth in this letter; and (4) the conversion of outstanding preference shares of the Company into Shares,
provided that any such shares received upon such conversion shall be subject to the restrictions on transfer set forth in this letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything herein
to the contrary, nothing herein shall prevent the undersigned from establishing a 10b5-1 trading plan that complies with Rule 10b5-1 under
the Exchange Act (&ldquo;<U>10b5-1 Trading Plan</U>&rdquo;) or from amending an existing 10b5-1 Trading Plan so long as there are no sales
of Lock-Up Securities under any such 10b5-1 Trading Plan during the Lock-Up Period; provided, however, that any public announcement or
filing under the Exchange Act regarding the establishment or amendment of such 10b5-1 Trading Plan shall clearly disclose that no Shares
shall be disposed by such plan during the duration of the Lock-Up Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned also agrees
and consents to the entry of stop transfer instructions with the Company&rsquo;s transfer agent and registrar against the transfer of
the Lock-Up Securities except in compliance with the foregoing restrictions. This lock-up agreement shall automatically terminate, and
the undersigned shall be released from the undersigned&rsquo;s obligations hereunder, upon the earliest to occur, if any, of (i) prior
to the execution of the Underwriting Agreement, the Company advises the Representative in writing that it has determined not to proceed
with the Public Offering; (ii) the Underwriting Agreement is executed but is terminated prior to the closing of the Public Offering (other
than the provisions thereof which survive termination), or (iii) November 30, 2025, in the event that the Underwriting Agreement has not
been executed by such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This agreement shall be governed
by, and construed in accordance with, the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGE FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><FONT STYLE="background-color: white">Very truly yours,</FONT></TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><FONT>Name
of Security Holder <I>(Print exact name</I>) </FONT></TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%">&nbsp;</TD>
  <TD STYLE="width: 4%"><FONT STYLE="background-color: white">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD><FONT>Signature
</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><FONT STYLE="background-color: white">If
not signing in an individual capacity:</FONT></TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><FONT>Name
of Authorized Signatory <I>(Print</I>)</FONT></TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><FONT>Title
of Authorized Signatory <I>(Print</I>)</FONT></TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><FONT><I>(indicate capacity
of person signing if signing as custodian, trustee, or on behalf of an entity)</I></FONT></TD>
  </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 40; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ea026414901ex5-1_moonlake.htm
<DESCRIPTION>OPINION OF WALKERS (CAYMAN) LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 5.1</B></P>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><IMG SRC="ex5-1_001.jpg" ALT=""></P>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 57%; font-size: 10pt">5 November 2025</TD>
    <TD STYLE="width: 43%; text-align: right; font-size: 10pt">Our Ref: SF/af/M6993-172608</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MoonLake Immunotherapeutics</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Walkers Corporate Limited</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">190 Elgin Avenue</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">George Town</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Grand Cayman KY1-9008</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cayman Islands</P></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Addressees</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>MoonLake
Immunotherapeutics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have been asked to provide this legal
opinion to you with regards to the laws of the Cayman Islands in connection with the Registration Statement (as defined in Schedule
1) filed by MoonLake Immunotherapeutics (the &ldquo;<B>Company</B>&rdquo;) with the United States Securities and Exchange Commission
pursuant to the United States Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), and the Prospectus
Supplement (as defined in Schedule 1) thereto relating to the offering, issue, and sale (the &ldquo;<B>Offering</B>&rdquo;) by the
Company of 7,142,857 Class A ordinary shares (the &ldquo;<B>Shares</B>&rdquo;), par value US$0.0001 per
share in the capital of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the purposes of giving this opinion, we have
examined and relied upon the originals or copies or translations of the documents listed in Schedule 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are Cayman Islands Attorneys at Law and express
no opinion as to any laws other than the laws of the Cayman Islands in force and as interpreted at the date of this opinion. We have not,
for the purposes of this opinion, made any investigation of the laws, rules or regulations of any other jurisdiction. Except as explicitly
stated herein, we express no opinion in relation to any representation or warranty contained in the Documents nor upon matters of fact
or the commercial terms contemplated by the Documents Based upon the foregoing examinations and the
assumptions and qualifications set out below and having regard to legal considerations which we consider relevant, and under the laws
of the Cayman Islands, we give the following opinion in relation to the matters set out below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The Company is an exempted company duly incorporated with limited liability, validly existing under the
laws of the Cayman Islands and in good standing with the Registrar of Companies in the Cayman Islands (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Registrar</B></FONT>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 8pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 8pt Times New Roman, Times, Serif">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Walkers</B></FONT></P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">190
    Elgin Avenue, George Town</FONT></P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Grand
    Cayman KY1-9001, Cayman Islands</FONT></P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>T</B>
    +1 345 949 0100 <B>F</B> +1 345 949 7886 www.walkersglobal.com</FONT></P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Bermuda
    | British Virgin Islands | Cayman Islands | Dubai | Guernsey | Hong Kong | Ireland | Jersey | London | Singapore</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>WALKERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">The Shares have been duly authorised by all necessary corporate action of the Company. Upon the issue
of the Shares (by the entry of the name of the registered owner thereof in the Register of Members of the Company confirming that such
Shares have been issued credited as fully paid), delivery and payment therefore by the purchaser (for consideration not being less than
their par value) in accordance with the Memorandum and Articles of Association (as defined in Schedule 1) and the Underwriting Agreement
(as defined in Schedule 1) and in the manner contemplated by the Prospectus Supplement, the Shares will be validly issued, fully paid
and non-assessable (meaning that no additional sums may be levied in respect of the Shares on the holder thereof by the Company).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing opinion is given based on the following
assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The originals of all documents examined in connection with this opinion are authentic. The signatures,
initials and seals on the Documents (as defined in Schedule 1) are genuine and are those of a person or persons given power to execute
the Documents under the Resolutions (as defined in Schedule 1). All documents purporting to be sealed have been so sealed. All copies
are complete and conform to their originals. Any translations are a complete and accurate translation of the original document they purport
to translate. The Documents conform in every material respect to the latest drafts of the same produced to us and, where provided in successive
drafts, have been marked up to indicate all changes to such Documents.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">We have relied upon the statements and representations of directors, officers and other representatives
of the Company as to factual matters.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">The Memorandum and Articles of Association reviewed by us will be the memorandum and articles of association
of the Company in effect upon the issuance of the Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">The Prospectus Supplement and the documents or agreements referred to therein will be duly authorised,
executed and delivered by or on behalf of all relevant parties prior to the issue and sale of the Shares and will be legal, valid, binding
and enforceable against all relevant parties in accordance with their terms under all relevant laws (other than the laws of the Cayman
Islands).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">The Company will offer, issue and sell the Shares in the manner contemplated by the Underwriting Agreement
and in the manner contemplated by the Prospectus Supplement and the documents or agreements referred to therein and otherwise in compliance
with all applicable United States federal and state securities laws.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">The Company Records (as defined in Schedule 1) are complete and accurate and all matters required by law
and the Memorandum and Articles of Association to be recorded therein are completely and accurately so recorded.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify">The accuracy and completeness of all factual representations made in the Prospectus Supplement and the
Registration Statement and all other documents reviewed by us.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify">The Company will receive consideration in money or money&rsquo;s worth for each of the Shares when issued,
such price in any event not being less than the stated par or nominal value of each Share.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify">The Resolutions are and shall remain in full force and effect and have not been and will not be rescinded
or amended. The Resolutions have been duly executed (and where by a corporate entity such execution has been duly authorised if so required)
by or on behalf of each Director / member of the Pricing Committee and the signatures and initials thereon are those of a person or persons
in whose name the Resolutions have been expressed to be signed. The Pricing Committee Resolutions (as defined in Schedule 1) were duly
adopted at a duly convened meeting of the Pricing Committee of the Company and such meeting was held and conducted in accordance with
the Memorandum and Articles.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>WALKERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify">The Documents, have been, or will be, duly authorised, executed and delivered by or on behalf of all relevant
parties and are, or will be, legal, valid, binding and enforceable against all relevant parties in accordance with their terms under all
relevant laws (other than the laws of the Cayman Islands).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: justify">The choice of the laws of the jurisdiction selected to govern each of the Documents has been made in good
faith and will be regarded as a valid and binding selection which will be upheld in the courts of that jurisdiction and all relevant jurisdictions
(other than the Cayman Islands).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.</TD><TD STYLE="text-align: justify">All preconditions to the issue of the Shares under the terms of the Underwriting Agreement will be satisfied
or duly waived prior to the issue of the Shares and there will be no breach of the terms of the Underwriting Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.</TD><TD STYLE="text-align: justify">The issue of the Shares will be of commercial benefit to the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">14.</TD><TD STYLE="text-align: justify">No invitation has been made or will be made by or on behalf of the Company to the public in the Cayman
Islands to subscribe for any of the Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.</TD><TD STYLE="text-align: justify">There are no provisions of the laws of any jurisdiction outside the Cayman Islands which would be contravened
by the issuance and allotment of the Shares and, insofar as any obligation expressed to be incurred under any of the Documents is to be
performed in or is otherwise subject to the laws of any jurisdiction outside the Cayman Islands, its performance will not be illegal by
virtue of the laws of that jurisdiction.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">16.</TD><TD STYLE="text-align: justify">There is nothing under any law (other than the laws of the Cayman Islands) which would or might affect
any of the opinions set forth above.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.</TD><TD STYLE="text-align: justify">There will be nothing in the Prospectus Supplement which would or might affect any of the opinions set
forth above.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">18.</TD><TD STYLE="text-align: justify">The Company was, or will be, on the date of execution of the Documents to which it is a party able to
pay its debts as they became due from its own moneys, and any disposition or settlement of property effected by any of the Documents is
made in good faith and for valuable consideration and at the time of each disposition of property by the Company pursuant to the Documents
the Company will be able to pay its debts as they become due from its own moneys.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">19.</TD><TD STYLE="text-align: justify">On the date of issuance of any Share, the Company will have sufficient authorised and unissued share capital.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">20.</TD><TD STYLE="text-align: justify">No amounts paid to or for the account of any party under the Documents or any property received or disposed
of by any party to the Documents in each case in connection with the performance of the Documents or the consummation of the transactions
contemplated thereby, represent or will represent proceeds of criminal conduct or criminal property as defined in the Proceeds of Crime
Act (as amended) (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>POCA</B></FONT>&rdquo;) or terrorist property
as defined in the POCA or the Terrorism Act (as amended) (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Terrorism
Act</B></FONT>&rdquo;), each of the Cayman Islands.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>WALKERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">21.</TD><TD STYLE="text-align: justify">As a matter of all relevant laws (other than the laws of the Cayman Islands) none of the Documents constitute
a security interest.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The opinions expressed above are subject to the
following qualifications:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The term &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>enforceable</B></FONT>&rdquo;
and its cognates as used in this opinion means that the obligations assumed by any party under the Documents are of a type which the courts
of the Cayman Islands (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Courts</B></FONT>&rdquo; and each a &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Court</B></FONT>&rdquo;)
enforce. This does not mean that those obligations will necessarily be enforced in all circumstances in accordance with their terms. In
particular:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">enforcement of obligations and the priority of obligations may be limited by bankruptcy, insolvency, liquidation,
restructuring, reorganisation, readjustment of debts or moratorium and other laws of general application relating to or affecting the
rights of creditors or by prescription or lapse of time;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">enforcement may be limited by general principles of equity and, in particular, the availability of certain
equitable remedies such as injunction or specific performance of an obligation may be limited where a Court considers damages to be an
adequate remedy;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">claims may become barred under statutes of limitation or may be or become subject to defences of set-off,
counterclaim, estoppel and similar defences;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">where obligations are to be performed in a jurisdiction outside the Cayman Islands, they may not be enforceable
in the Cayman Islands to the extent that performance would be illegal under the laws of, or contrary to the public policy of, that jurisdiction;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">a judgment of a Court may be required to be made in Cayman Islands dollars;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">to the extent that any provision of the Documents is adjudicated to be penal in nature, it will not be
enforceable in the Courts; in particular, the enforceability of any provision of the Documents that is adjudicated to constitute a secondary
obligation which imposes a detriment on the contract-breaker out of all proportion to any legitimate interest of the innocent party in
the enforcement of the primary obligation may be limited;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">to the extent that the performance of any obligation arising under the Documents would be fraudulent or
contrary to public policy, it will not be enforceable in the Courts;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>WALKERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">in the case of an insolvent liquidation of the Company, its liabilities are required to be translated
into the functional currency of the Company (being the currency of the primary economic environment in which it operated as at the commencement
of the liquidation) at the exchange rates prevailing on the date of commencement of the voluntary liquidation or the day on which the
winding up order is made (as the case may be);</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">a Court will not necessarily award costs in litigation in accordance with contractual provisions in this
regard; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify">the effectiveness of terms in the Documents excusing any party from a liability or duty otherwise owed
or indemnifying that party from the consequences of incurring such liability or breaching such duty shall be construed in accordance with,
and shall be limited by, applicable law, including generally applicable rules and principles of common law and equity.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">Our opinion as to good standing is based solely upon receipt of the Certificate of Good Standing (as defined
in Schedule 1) issued by the Registrar. The Company shall be deemed to be in good standing under section 200A of the Companies Act on
the date of issue of the certificate if all fees and penalties under the Companies Act have been paid and the Registrar has no knowledge
that the Company is in default under the Companies Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion is limited to the matters referred
to herein and shall not be construed as extending to any other matter or document not referred to herein.&nbsp; This opinion is given
solely for your benefit and the benefit of your legal advisers acting in that capacity in relation to this transaction and may not be
relied upon by any other person, other than persons entitled to rely upon it pursuant to the provisions of the Securities Act, without
our prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion shall be construed in accordance
with the laws of the Cayman Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the filing of this
opinion as Exhibit 5.1 to the Company&rsquo;s Current Report on Form 8-K filed on November 5, 2025, and further consent to all
references to us in the Registration Statement and/or Prospectus Supplement under the caption &ldquo;Legal Matters&rdquo; and any amendments
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yours faithfully</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Walkers (Cayman) LLP</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">Walkers (Cayman) LLP</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="text-transform: uppercase"><B>WALKERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Schedule
1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">LIST OF DOCUMENTS
EXAMINED</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The Certificate of Incorporation of the Company dated 13 August 2020, the Certificate of Incorporation
on Change of Name dated 5 April 2022, the Second Amended and Restated Memorandum and Articles of Association of the Company adopted on
31 March 2022 and effective 5 April 2022 (the &ldquo;<B>Memorandum and Articles of Association</B>&rdquo;) and each of the Register of
Directors, Register of Officers and Register of Mortgages and Charges of the Company (together, the &ldquo;<B>Company Records</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">The Cayman Online Registry Information System (CORIS), the Cayman Islands&rsquo; General Registry&rsquo;s
online database, searched 5 November 2025.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">A Certificate of Good Standing dated 5 November 2025 in respect of the Company issued by the Registrar
(the &ldquo;<B>Certificate of Good Standing</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">A copy of the executed written resolutions of the Directors of the Company dated 4 November 2025 and a
copy of the executed minutes of a meeting of the Pricing Committee of the Company dated 4 November 2025 setting out the resolutions adopted
at such meeting (the &ldquo;<B>Pricing Committee Resolutions</B>&rdquo; and together, the &ldquo;<B>Resolutions</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">Copies of the following documents (the &ldquo;<B>Documents</B>&rdquo;):</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Registration Statement on Form S-3 (File No. 333-274286) filed on 31 August 2023 containing a base
prospectus (as amended and supplemented from time to time) relating to the offering, issuance and sale of up to a maximum offering price
of US$1,000,000,000 of certain securities in the Company (the &ldquo;<B>Registration Statement</B>&rdquo;);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a prospectus supplement to the Registration Statement relating to the issuance and sale of the Shares
(the &ldquo;<B>Prospectus Supplement</B>&rdquo;); and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the executed Underwriting Agreement dated 5 November 2025 among the Company and the Underwriters named
therein relating to the issuance and sale of the Shares (the &ldquo;<B>Underwriting Agreement</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  < (\# 2(  A$! Q$!_\0
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M^[PMH:7EUJVJW?AZ"Z\4ROKUM?:I>>&I(/T5_9)_X)D?M"?LL?M ?#+XI_\
M!-#_ (*E>)?CO^Q'XD\/^,=%^-/PB_:A^)8_:E\*V.H6OAJZMOA_KOPJUKP+
M?:%IJ7/_  E@B_M6'3;WPA<:78Z?-%/J7B:SNI-&MP#\,?\ @@%_RE,^"/\
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M]*\!?M%_L]_"/XT^$M @^S>'M(^(W@?0O$Z^'(OLJV1'AR\U*SFU'P^YM52
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>M=:\065DNNZO:1W"+/%:ZEJ-U!%,!+'&C_-0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>mltx-20251105.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qRZo7xRiXhun8uNbXQsSaiFGaPtypR1KYkxs2twHSmqHygqrhKBcSHXRvgWwYMB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:MLTX="http://moonlaketx.com/20251105" elementFormDefault="qualified" targetNamespace="http://moonlaketx.com/20251105">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://moonlaketx.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="mltx-20251105_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="mltx-20251105_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>mltx-20251105_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>mltx-20251105_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="mltx-20251105.xsd#Cover" roleURI="http://moonlaketx.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://moonlaketx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 05, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  05,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MOONLAKE IMMUNOTHERAPEUTICS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001821586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1711963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Dorfstrasse 29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Zug<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">415108022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A ordinary share, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MLTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0264149-8k_moonlake.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0264149-8k_moonlake.htm">ea0264149-8k_moonlake.htm</File>
    <File>mltx-20251105.xsd</File>
    <File>mltx-20251105_lab.xml</File>
    <File>mltx-20251105_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0264149-8k_moonlake.htm": {
   "nsprefix": "MLTX",
   "nsuri": "http://moonlaketx.com/20251105",
   "dts": {
    "inline": {
     "local": [
      "ea0264149-8k_moonlake.htm"
     ]
    },
    "schema": {
     "local": [
      "mltx-20251105.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mltx-20251105_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mltx-20251105_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://moonlaketx.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-11-05",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0264149-8k_moonlake.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-11-05",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0264149-8k_moonlake.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001213900-25-106723-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-106723-xbrl.zip
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M7&)K.2&]4<ER:\3=G\S!U.&MJ+GFXX3IO>UP4^,V-0@;,VWH\CO,^L$BPQR
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MMP6I+TO <VMTFH"']3W]=&&?BL;+[T='1. M[E$(W9,0F]R$[EEXJW>T'TQ
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MHMH(.)J<LJY(K7V^( 0R/(4-08XID_T]?7.EOD,$+T>WC[RM9HT]\&JSI$8
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M*T%6)K=HP7^"CNM32\GT&QOAHY14]!$ZBFP%4E*?03U%GZJ=YK//J9X^6O^
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MTP9/8*X.&CWC=C=6)$4UGU$R<Q07J,=77T TG]LZ@&(\-%/L2,?*;B*;DC7
M'E=,YKA3K]#?'W=!?3;V(P9]<,[0?%7FH7-+AD^Q36>F:4XO:& Z=;S%GG _
M\?TNA]13A\D_^C Q]SAO?0O'Z5B?8#76->\4U=INKL/F-?V0QW0'!CP*U2KG
MX< YD8VVQ+&E!KT6MQ35) IH8^5,R</.&UTB^3]16VZ5DEGBX(1JZ5=Y:I&G
MMMH9,;:&EM:)-[4>.V5B79,VF'(*I&(P4KPAG1QS[DY9'3T#BRN[!S;&+IL=
MHTV%+;! I:F(:R&4_W(F.E?<4TV-$5(96T/$^ZW";$;\5US*NM/S;967:D%C
MYIP"GWY&C(CK8IKYYNJ; 'WF<BJDP;CBAGM]R%UY8MVZ.MD>H2YKPAYP.*^+
MK6':#0<3VJ1J=*EM^IELTG"(]Z)_[+F[,"U#>RC2+41B(A#$B7T7\P[FSI6Z
M2!H?A4UI=J)NXFZ3.BET94UXT3I;+X@)L_<#0F&M"IK#WGZC/4*GO DGTQ:3
MV:B;D54SD]' @D>^AH($2%*;\]DEH0*Y;L^5LI&BB-J\964W>/J(IX195/*%
M&G:&L-:I[SDA  \V,%U#/A%9)\9I:B10] EBZ:CLETG7<!&LWT8# SN>,-K)
MV]T+6S?TH/M.R$Z_8A3_)OO!Z-BAM+@27X?BDR75#:AUE:->)>U^[U)I%H6#
M-!LI/+JNM.>E"KL;R" \Y0(4?5?@UPR\95C&;DV+*8P&-)YSGX6RS=/[Q3L3
M=V#3S-\BY (+58K-_",*49N[*R&W.V'=4GGE/.Y6>=>)FR"T6B#(N2P%;G&*
M;(_LV#1#W,% W"MU\OTA=2*ID^\/J9.O2KK!_1GO!/V&C@OGYWAUS?9>$TT2
M#FB9Q-G)Z?T1&AI;T3A612$Q!CN6'5::.XFFPV&]X\O4>=,1B@>\'\=$+P8F
M#R B 9>R</2^PR;%H0%G,-C,>\BC3YJ^\W>3$$, 51 )/3_U?\ZKCIH<]+HF
M(#&3=P(/JIJ$V37/6S1<H@++_V\:MH:'/<M6"=52)=1AH5P58'HTP[9ZMJ"H
M!X!GQ)J)A:/,T5VI65Q^K) %7XY,X<]]K9'%%A,#,=?@P&I[QTHQV(D7KB4:
MC01KXZB_MR96[@98_2&^)5H-DE2)1S;6A*TRT<5)61U<&8M489!*<"XV+U)7
M2S?!.L&L)>$9@V1&FN%(8:_674,-T#%KXM\3 25CMI*YQ%8\N?JZF(J'RJ1T
M3/=]RXH9I:U!10'G(*AML)8<U68("K=_(>>S%^3U%J13!"QR%][Q[AF-M92Q
MD)\ FJ=K"9^5W,14&QZ;NO 8]D%Z*6\=5C#IK%/9D_M-!6*[J%*$8Z5K</99
MQ:'J!,%8PL=!<91<68/Y6.-O(^R?)]/M(*J@NU _A5C7ZW#W. Z L8R!C_3G
MM:TX]9A6,]-:6V<K!7^Q8WY.,AA.*1K"AOF-];#K2D>BC&G4 IVUAJ775Q,E
M"[A][!K?2ZA%MCG,A]__A(VZ4:SF/J#P_8I()_&:[PA:BO%=E 7<.A1PV-K*
M A\PZX<#7=0.LV:68#&H,QNXM[GK\+,CCO41W)+]%.Y>[K?<1:AE..17+4&#
M-,(NPZ&L*=_=9W043S'9I0?[TO!37LL3!ED:D_[M!WQ<?:2M\?#1D-WM=S&6
MX"CN?=$,KQ!'FJI!%SV/;*9G5[66=/*<7.;7@F>&:W/.%&]@CU'M]$KZ5Z(&
M1%Z)I1R/[E8H-=0I!.'$:+03Z#X.3L :4982WWI^36Q>EE4Z*ZJ;X_E,$E8,
MHA2)I]F'F^JAFJ\M!2BA"BG1S6&<7O0FDAY4VW'],<QE#C.2)@C',:YIU1T=
M]8TZG2LLRZ:)0<LF56-C."OT&<>JYC,)3/4#4@/-@ECT+Z)3B$,-^W"B%'&H
MEJ7,_!:F+<C_RZX3^A.7#H!7:7%I%]L3KHG8(Q+27QRPL2<.##H.]72\_5R,
MR8X>GHXC1P<U R8J2$=/:0^;WO+9<FYLU-&P$W(MMHDO[V?[ 4D2V( *XX%H
MY:"8+-A",B 80@JS"K<%IO.9-G(3UBM<)]S0TD64;^^B/-RYYMBG E@>.%;'
MX6&-!L:V5I/VI4GTH"["YT;$'R6!?7I@4/TZ+/'LK^/!2V$O1=T4I,OC/DS!
MB8KJYE72I,F?T4O&JXVR.P69CSX4:1_*8*4#L]2QM+:.POX!KJ+[Z]%1:KO/
M$-/?>):,&>H,I9I/<+B[W3]:#.[&A5"U-BV"P;"FD]D0>"?H,<P96(IAOJ!G
M (Y0UC&715FIA@-; -:,-*6<1TZ/%OG[K' !;SY !>E![7.TA4V0:JD#!3D=
MJW8O3,JI$%3BV&\H9\RO)VI:,:RFS55&H0/1*;Z'A.V,H_1M\$"9S=S:>?1X
M\TK#'@UT8M$X>W2@HT1C?!P@3479ZN^XMBD1SE4>Q;!06<+8T2O[)G"]; 5R
MF%/6KR */$MB:\F+]8$JO93=00D=?7 T<S92\I+8,YXQ>X8$1:H>IX9;6Q2;
M:IN-$DE,^7U<Q4?4!..)B?G,,,CE*.9H$6:EE,B!$)>:%>WG1,@4OB&4%Y^N
MBO6-)^[B7PP.WX4UX-VK.2X"5\8Y]6I*"B\$Z BI[(C1&>O/80T[;$D-9WS=
M^#B($. M8:6JM3+@^5::WOQ#:,$GN8P6_ODQZY8WOB&N<)XGH,SDK'*+Z=:N
M=VOBZ>3+Q0CDIF#:B(4TOK0* UVTS'8'XT9)(U!SL(&*:3S2Y*(5U=59#8Q8
MCK;TL+JHY@BJ"\8FE2158 ]>EO1GOV,/PMWKW'4R0_CI55Z3S&&@NU*]";84
ME=/KU,?N70R#X8TP6(&[5D<< Y1BTW%RP-9 _^AN25%=5EVC(Z;HT>!GL=BD
M)%A?/EIQT+7[9!!_.&00)8/XPR&#^%5)]]&',4-"@F5(7V=SB'1*1P4H%O(G
M@ZCSQOUD#S#YX'0R6/)*F J9(78D;'^G8X\BB;[8JM<<74?,DL?(S'MOL?UX
MQ?BG9W5W"0Z>B;HCYY]W6UX\.P]]%KS%\PX'G931KW#W)7(+1.<4J+>_?/YK
M\$M]#='],9]A<,YHN,4'\4,F-+XQ677CP?P6]FLC% A(>= (I$\8$D=:L%&C
M3M.8CY&Q+NKZ^5GS$]^U=!#;%=[N?'DU..S<0,QIEZ]<=U)T0O@P8R]P/Z&)
M;V6*G.!CF,_XR'R\OTFE+5%TK[$=%1B[_>QTL/AD);D,D29W&/55VQLM!!C6
MZZ\\1G1'&5!Z16:N&#7""($7.QJ^ILO;V+Q(C+5F9$8A,P"(]%(D@SM1NS2?
MYJ@LEX Z]LH-V!-WE\"B%\SK5!0'B 1(([G@R #(VYL9/I10DZO/V6@=20/S
MFYU[>^ZEQ#^#:.-K%*U6B;=IELP:NX?3RHZ/7-;&#UT;H*29*YCGF#1/,O)^
MCDQ8?_:#J26;U:LW28N-K"LUJ\Z79N03T^UB+^S6L:U?,:&D4B+ U[IZR.>%
MZ>M8J?PQ69S"*<0RBQTF!Y'<^<Q.;C_P<^=Y[L^KB8L?K%H\]QW6@DJ+EELZ
M^86:8^38]V%[$[#WD("1Y+[+$$R=))^:CAR<)+&D_1<[P903*"'!"O3/(3QG
MW,V"ACJVH9"'Z%=[="H)6N>63;5*:H%H;)G/MFZ%#$H3=E(D:0"]#J71RDC@
MLB8.745=GL:L3S-<()M2I<H.?-TXR!=*^=GD.%JIEIL*6W^V"1L6-#<NT>..
M9#;B."X0793$</(N^8"(H49<$E)9V,J1KOT[MP9T?='EAF_RYGWT@D,]_>^4
MA?LOZS1IKAY?@"(D"$E'FDS,UEM^A'/R:U:#E_?W+"G:JR4: /_Z2W(>'3U+
M:NQ0EL+6^B5#0,#V.'H)FAI>P*#3=M_>:]?YS./X^C]Z2?:\,?ECRW2\JUK<
M76ADF!O#F'76ZE[V&ZA(OF561R>1L9'$X.1B0H*N::P]2#W>5!ZU&-(+YLZ>
M8Y+V^IBAW#FF1<=6(QHQB/&#/*Z[4D+C&!R\3.HT".#[QC!TP+:DDRAD4V8W
M?#_:!A8N(J$D#\SQVS_ EH64%)2_Z%OV9KNI7T(=AQRJ,5"X4[>+Q'H?5\7Q
M;M7/)64>H^JFI:9*,YH(6%M70AE:NWLZB-.!;-,)A1U1UIALL4FIDB(':(Z#
M*8Z= XR#HN78_0J.\AAD=9E3*<-H-?+!<B'+90PF^J*K:8G>F&2HRX%(4ZN8
MFT->HV==L#*-<0^1I=JC&$QL0:D_,X> /=D#/<@S"+TRLBN+FC"9#[UXI.C_
M( ;UB$/'(BQ0/^N8:UO:00W]QZ'+!")T-V#90@D ;HD(S&=?'%?FXNG'#K7-
M1K^!:L-F+F!/IEO?_*P2_FV*,"EK@9OCL59W)NC/.0>+5Z^C)T4'XWJ_E22
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M&B%L<NW%I2K)CO06&8VJ,2Y/R2?HP\?><+_[A@/N2KX3T_70JP;%-Z[[K6O
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M)5HY.;DGT."<0YA>FCAR(31N$DQ=2C"^E:5&%'=%)=&HS2^QZ%+"3ZE'NYI
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MP/ITD%]G4_?:O:(VW1LJ\/=3P_ACU/^: 1QH@S7%WX:&Q-41(;(HM:>&7N&
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M/?M)\Q:%.I\2A3*M3KM> 8\VY7%@JE<+,RDR3#IKG,HY=SE69,J%N'.<AD)
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M2NH@O6O$A["=;<>PL[;>HH9N:!('1@NBQ.S!((_Y,#2D:4XXB%&B:"5AJYL
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MP$#Z=U0E[XY.#J@__FCGCZ<?CVW;WH^[%SOB@?E53!'!__W?,-A<WWS^XWY
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MZZQA%X5Z3->?*4<T.+ADL2"+4V!XFH5_&KW)\S3/P=J#Q2H2E%K\S(&ZS7B
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M'+;'5;Z2\8X3IV+/S,ZG+8B$)"04R0%)*]J:'[]] "1(T8Z<U\HUFJJ);1Y
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M,BKQ?; H"88 NS @[L(>U2UR2PLZ7SG#(2'TT'R<C FKX8QCZ(?ZHXZ6C+1
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M;V]N;&%K92YH=&U02P$"% ,4    " !$BV5;,LF$<6"P  !FM , '0
M        @ &J%   96$P,C8T,30Y,#%E>#$M,5]M;V]N;&%K92YH=&U02P$"
M% ,4    " !$BV5;?VVN1\X:   3K   '0              @ %%Q0  96$P
M,C8T,30Y,#%E>#4M,5]M;V]N;&%K92YH=&U02P$"% ,4    " !$BV5;8.(\
MO"@#  #H"P  $0              @ %.X   ;6QT>"TR,#(U,3$P-2YX<V10
M2P$"% ,4    " !$BV5;F&0V[OT*  !_A@  %0              @ &EXP
M;6QT>"TR,#(U,3$P-5]L86(N>&UL4$L! A0#%     @ 1(ME6[E8_RA;!P
MV%<  !4              ( !U>X  &UL='@M,C R-3$Q,#5?<')E+GAM;%!+
4!08     !@ & *(!  !C]@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>ea0264149-8k_moonlake_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mltx-20251105.xsd" xlink:type="simple"/>
    <context id="AsOf2025-11-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
        </entity>
        <period>
            <startDate>2025-11-05</startDate>
            <endDate>2025-11-05</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-11-05" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-11-05" id="Fact000004">0001821586</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-11-05" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-11-05" id="Fact000010">2025-11-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-11-05" id="Fact000011">MOONLAKE IMMUNOTHERAPEUTICS</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-11-05" id="Fact000012">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-11-05" id="Fact000013">001-39630</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-11-05" id="Fact000014">98-1711963</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-11-05" id="Fact000015">Dorfstrasse 29</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-11-05" id="Fact000016">6300</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-11-05" id="Fact000017">Zug</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="AsOf2025-11-05" id="Fact000018">CH</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="AsOf2025-11-05" id="Fact000019">41</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-11-05" id="Fact000020">415108022</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-11-05" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-11-05" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-11-05" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-11-05" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-11-05" id="Fact000025">Class A ordinary share, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-11-05" id="Fact000026">MLTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-11-05" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-11-05" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
